Stereocomplexes for delivery of anticancer agents
Patent Information
- Application Number
- JP2024034842
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-08-30
- Filing Date
- 2024-03-07
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-12-03
AI Technical Summary
Current methods for delivering hydrophobic anticancer drugs face challenges in maximizing biocompatibility, minimizing toxicity, and ensuring targeted delivery to tumor sites while avoiding systemic side effects, particularly in personalized cancer treatments involving multiple agents.
The development of stereocomplexes composed of PDLA and PLLA polymers, which form a controlled release system for anticancer drugs, allowing for synergistic delivery and customizable treatment based on specific tumor types, with optional targeting and functional groups.
The stereocomplexes provide low toxicity, biodegradability, and controlled release of anticancer drugs, effectively reducing tumor size with minimal side effects and enhancing treatment efficacy across various cancer types.
Smart Images

Figure 2024053046000001 
Figure 2024053046000002
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 775,076, filed December 4, 2018, and No. 62 / 893,863, filed August 30, 2019, which are incorporated by reference in their entireties. [Background technology]
[0002] background The delivery of hydrophobic drugs to the appropriate tissues in the body has long been a challenge for medical researchers who must minimize toxicity while maximizing biocompatibility. An ideal delivery vehicle avoids premature release of its cargo, thereby delivering a higher dose of drug to the effective site. Furthermore, it is highly desirable to avoid affecting non-target tissues in order to maximize the treatment of the target area and avoid systemic effects. This is a concern, especially in cancer research, where many anti-cancer chemotherapeutic agents are hydrophobic and may have toxic side effects. Chemotherapeutic agents, especially those with low molecular weight, may enter all types of cells by random diffusion, which reduces their availability at the tumor site and also leads to systemic side effects. Random diffusion may also result in rapid cellular uptake rather than extended therapeutic effects. Finally, drugs may be rapidly removed from the bloodstream by filtration by the kidney.
[0003] Furthermore, personalized cancer treatment is becoming more and more possible.Using such an approach, chemotherapy agents or combinations of chemotherapy agents can be selected to treat a particular tumor of a subject more effectively than a general course of chemotherapy.Ideally, chemotherapy agents can be selected based on tests such as biopsy, cell culture and sensitivity assays, rather than performing expensive genetic tumor profiling.
[0004] Furthermore, in some cases, it may be clinically desirable to treat subjects with cancer with more than one chemotherapy agent at the same time.However, individual chemotherapy agents often exhibit toxic side effects, and the combined side effects of two or more chemotherapy agents may be intolerable to subjects.
[0005] Currently, drug polymer conjugates are of great interest due to their desirable properties, including low toxicity and local delivery, in treating various forms of cancer.Although many drug polymer conjugates have been successfully tested, tumor cells often develop resistance to single-drug therapy.Combination therapy using drug polymer conjugates has been developed, but most of these have not yet been extensively tested in vivo.
[0006] What is needed is a method for treating cancer or reducing tumor size in a subject that minimizes toxicity and is biocompatible, provides targeted delivery of anticancer drugs to tumor cells by drug polymer conjugates or similar means without adversely affecting surrounding tissue, shows sustained release rate control for anticancer drugs, and allows synergistic combination of two or more anticancer drugs without concomitant increase in side effects.Ideally, the method can also be customized for individual patients. Summary of the Invention [Means for solving the problem]
[0007] overview Disclosed herein are stereocomplexes for the delivery of one or more anticancer drugs. The stereocomplexes exhibit low toxicity and are biodegradable while still achieving controlled release of one or more anticancer drugs at tumor sites. The stereocomplexes can be designed so that the anticancer drugs work synergistically, and may contain additional targeting and functional groups, if necessary. The stereocomplexes disclosed herein can be combined with pharma-ceutically acceptable carriers and / or excipients to form pharmaceutical compositions. By varying the amount of each anticancer drug in the stereocomplex, specific types of tumors and cancer cell lines can be treated.
[0008] Advantages of the materials, methods and devices described herein are set forth in part in the description which may be followed or taught by the practice of the embodiments described hereinafter. The advantages described below will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive.
[0009] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several aspects described below. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 shows a schematic diagram of a stereocomplex disclosed herein that contains two different drugs, based on stereocomplex formation between PLLA and PDLA.
[0011] [Diagram 2]FIG. 2 shows a schematic diagram of a polymer-conjugated drug (PCD) for stereocomplex formation. In panel (a), the hydrophilic element protrudes into the solution, and the hydrophobic element is located in the particle core of the stereocomplex. In panel (b), examples of anticancer drugs conjugated with hydrophobic moieties having cleavable linkers are shown. In one example form, mertansine (DM1) is conjugated using a disulfide bond, while docetaxel (DTX) is conjugated using a hydrazone bond (linker 1), a disulfide bond (linker 2) or an ester bond (linker 3).
[0012] [Diagram 3] FIG. 3 shows the structures of cRGD-PEG-PDLA, FA-PEG-PLLA and methyl-α-glucose-PEG-PDLA.
[0013] [Figure 4] FIG. 4 shows the synthetic scheme for producing mPEG-PDLA-SS-DM1.
[0014] [Diagram 5] Figure 5 shows the H NMR of mPEG-PDLA-SS-DM1 in DMSO-d6. The lettered peaks correspond to the same letters in the inset structure; a: -CH- of PDLA; b and c: -CH3 of DM1.
[0015] [Figure 6] FIG. 6 shows a synthetic scheme for producing mPEG-PLLA-hydrazone-DTX.
[0016] [Figure 7] Figure 7 shows the H NMR of mPEG-PLLA-hydrazone-DTX in DMSO-d6. The lettered peaks correspond to the same letters in the inset structure; a: -NH- for DTX-hydrazone-OH; e: -CH- for PLLA.
[0017] [Figure 8] Figure 8 shows the H NMR of mPEG-PLLA-ester-DTX in CDCl3. Lettered peaks correspond to the same letters in the inset structure; c and d: -CH3 for DTX; e: -CH- for PLLA.
[0018] [Figure 9] FIG. 9 shows a synthetic scheme for producing mPEG-PLLA-SS-DTX.
[0019] [Figure 10] Figure 10 shows the H NMR of cRGD-amide-PEG-PDLA in DMSO-d6. Lettered peaks correspond to the same letters in the inset structure; a: =CH- of cRGD; b: -CH2- of cRGD; c: -CH- of PDLA.
[0020] [Figure 11] Figure 11 shows the H NMR of folate-amide-PEG-PLLA in DMSO-d6. The lettered peaks correspond to the same letters in the inset structure; a: =CH- of folate; b: -CH2- of folate; c: -CH- of PDLA.
[0021] [Figure 12] Figure 12 shows the H NMR of methyl-α-glucose-PEG-PDLA in CDCl3. The lettered peaks correspond to the same letters in the inset structure; a: -CH- of PDLA; b: -CH2- of PEG; c: -CH3 of glucose.
[0022] [Figure 13]FIG. 13 shows the combination index (CI, shown on the vertical axis) of free DM1 and DTX in various cell lines at various ratios of DM1 to DTX. CI is used for quantitative synergy determination of two combined drugs. Synergy is represented by CI<1, additive effect occurs when CI=1, and antagonism occurs when CI>1. Cell lines include A549 (human alveolar basal epithelial adenocarcinoma cells; red circles), NCI-H460 (non-small cell lung cancer cells; black squares), MiA PaCa-2 (pancreatic cancer cells, blue triangles), SGC-7901 (gastric cancer cells, teal triangles), and Hep3B2.1-7 (liver cancer cells, pink triangles).
[0023] [Figure 14] Figure 14A shows the particle size of the prodrugs mPEG-PDLA-SS-DM1 (D-DM1) and mPEG-PLLA-hydrazone-DTX (L-DTX). Figure 14B shows the particle size of the complexes produced by dialysis (left panel) and after lyophilization and reconstitution (right panel). Figure 14C shows the particle size of the complexes produced by using rotary evaporation (left panel) and after lyophilization and reconstitution (right panel).
[0024] [Figure 15] Figures 15A-15B show DSC results evaluating the melting temperature (Tm) of various formulations. Figure 15A shows the free DM1 powder (triangles), the lyophilized powder of mPEG-PDLA-SS-DM1 (circles), and the lyophilized powder of mPEG-PDLA (squares). Figure 15B shows the lyophilized powder of mPEG-PLLA-hydrazone-DTX (squares), the lyophilized powder of mPEG-PDLA-SS-DM1 (circles), and the lyophilized powder of the complex formed from the two polymers mentioned previously (triangles).
[0025] [Figure 16]Figures 16A-16B show the release of drug from the complex over time. Figure 16A is a graph showing the release of docetaxel over time from the complex at pH 7.4 (squares) and pH 5.5 (circles). This difference is due to the pH sensitivity of the hydrazone linker. Figure 16B shows the release of DM1 over time from prodrug D-DM1 formulations and complexes with and without glutathione (GSH) at pH 7.4. The complexes provide a much slower release than the prodrugs with GSH (circles and squares, respectively), while the DM1 conjugates with redox-sensitive disulfide linkers prevent the premature release of DM1 without GSH (complexes are represented by inverted triangles and prodrugs are represented by triangles overlapping the inverted triangles).
[0026] [Figure 17] Figure 17A shows the tolerability of various formulations in tumor-free mice with injections given on days 1, 8, 15 and 22. Figure 17B shows the weight change of tumor-free mice 3 weeks after injection of the complexes at 3.6 mg / kg DM1 once per week for 3 injections, 5 mg / kg DM1 once per 2 weeks for 2 injections, and 7 mg / kg DM1 once per only 1 injection, respectively.
[0027] [Figure 18]Figures 18A-18D show the in vivo antitumor efficacy of the complex in a subcutaneous BGC-823 (stomach) tumor model by intravenous injection. A human gastric cancer cell suspension was injected subcutaneously into the back of the mice to establish the tumor model. When the tumor volume reached approximately 60 mm3, groups of tumor-bearing mice (n=5) were injected with the stereocomplex via the tail vein on the days indicated by the arrows in panel (a) (i.e., days 1, 8 and 15 at a dose of 4 mg / kg DM1 and 36 mg / kg DTX per injection). Figure 18A shows tumor size measurements for the control group (squares) and the treated group (circles). No significant weight loss was observed in the treated or control groups (Figure 18B). Significant tumor reduction was achieved in the groups receiving the complex (resected tumors are illustrated in Figure 18C), and a greater overall reduction in tumor weight was achieved in the stereocomplex-treated group (Figure 18D).
[0028] [Figure 19] Figures 19A-19B show the in vivo antitumor efficacy of the complex in a subcutaneous MIA PaCa-2 (pancreatic) tumor model by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model. When the tumor volume reached approximately 140 mm3, a group of tumor-bearing mice (n=5) was injected with the complex via the tail vein once every two weeks. After two injections (i.e., days 1 and 14 at a dose of 5 mg / kg DM1 and 40 mg / kg DTX per injection), one mouse was tumor-free on day 24, and a total of three mice were tumor-free by day 38. Figure 19A shows the tumor size change for the group treated with the complex (circles) versus the control group (squares). Figure 19B shows the control mice (top row of photos) and treated mice (bottom row of photos) on day 29 of the study.
[0029] [Figure 20]Figures 20A-20B show a comparison between the complex and the prodrug in terms of in vivo antitumor efficacy and toxicity in subcutaneous MIA PaCa-2 when the treatment is delivered by intravenous injection. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model. When the tumor volume reached about 140 mm3, a group of tumor-bearing mice (n=5) was injected with the complex via the tail vein. After four injections of the D-DM1 prodrug and two injections of the complex, almost the same antitumor effect was observed (circles and triangles in Figure 20A, respectively), but the prodrug treatment induced mouse death and obvious weight loss (Figure 20B, circles), while the complex treatment group showed an increase in weight during the treatment period (Figure 20B, triangles).
[0030] [Figure 21] Figures 21A-21D show a comparison of in vivo antitumor efficacy and toxicity between the complex and control (no complex administration) in a subcutaneous Hep 3B2.1-7 (liver) tumor model when the treatment is delivered by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model. When the tumor volume reached approximately 130 mm3, a group of tumor-bearing mice (n=5) was injected with the complex via the tail vein. Figure 21A shows that the tumor volume continued to grow in the control group (squares) but dropped in the complex-treated group (circles). Figure 21B shows that the body weight of the complex-treated group remained almost the same throughout the study (circles), but dropped significantly in the control group (squares). Figure 21C shows tumors excised from the control group (top row) and the complex group (bottom row), and Figure 21D shows a comparison of tumor weight between the control group (left bar) and the complex group (right bar).
[0031] [Figure 22]Figures 22A-22D show the change in tumor size for the complex-treated group versus the control group in a subcutaneous HT-29 (colon) tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 100 mm3, a group of tumor-bearing mice (n=5) was injected with the composition via the tail vein. Figure 22A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed smaller final tumor volumes (arrows indicate the date of injection). Figure 22B shows the weight change for the control and treatment groups. Figure 22C shows the excised tumors for the control group (top row) and the stereocomplex-treated group (bottom row). Figure 22D shows a comparison of tumor weights for the control group (left side) and the stereocomplex-treated group (right side).
[0032] [Diagram 23] Figure 23 shows a comparison between the complex and the prodrug (D-DM1) for in vivo antitumor efficacy in a subcutaneous CNE (nasopharyngeal) tumor model when the treatment is delivered by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model. When the tumor volume reached approximately 100 mm3, a group of tumor-bearing mice (n=5) was injected with the complex via the tail vein. As shown, with an equivalent DM1 dose, the tumor volume continued to grow in the case of the prodrug group (squares), while the complex treatment (circles) showed good tumor growth inhibition efficacy.
[0033] [Figure 24]Figures 24A-24B show the in vivo antitumor efficacy of the complex in a subcutaneous NCI-H526 (small cell lung cancer) tumor model by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model. When the tumor volume reached approximately 100 mm3, a group of tumor-bearing mice (n=5) was injected with the complex via the tail vein once per week. After three injections, one mouse was tumor-free on day 18, and all mice were tumor-free by day 32. Figure 24A shows the tumor size change for the group treated with the complex (circles) versus the control group (squares). Figure 24B shows the control mice (top row of photos) and treated mice (bottom row of photos) on day 18 of the study.
[0034] [Diagram 25] Figures 25A-25D show the in vivo antitumor efficacy of the complex in a subcutaneous NCI-H1975 (non-small cell lung cancer) tumor model by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 130 mm3, a group of tumor-bearing mice (n=5) was injected with the composition via the tail vein. Figure 25A shows that untreated mice (squares) showed a more significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the date of injection) after only one injection. Figure 25B shows the weight change of the control and treated groups. Figure 25C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 25D shows a comparison of tumor weights of the control group (left side) and the stereocomplex-treated group (right side).
[0035] [Figure 26]Figures 26A-26D show the in vivo antitumor efficacy of the complex in a subcutaneous MDA-MB-231 (triple-negative breast cancer) tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and when the tumors reached approximately 100 mm3, a group of tumor-bearing mice (n=6) was injected with the composition via the tail vein. Figure 26A shows that untreated mice (squares) showed a more significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume after only one injection. Figure 26B shows the weight change of the control and treatment groups. Figure 26C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row), and it is noted that one mouse was tumor-free from day 23. Figure 26D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right).
[0036] [Figure 27] Figures 27A-27B show the in vivo antitumor efficacy of the complex in a subcutaneous MX-1 (breast) tumor model by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model. When the tumor volume reached approximately 530 mm3, a group of tumor-bearing mice (n=5) was injected with the complex via the tail vein. After only one injection, as shown in Figure 27A, the tumor size continuously decreased over the following 20 days, demonstrating the efficacy of the complex even in large tumors. No weight loss was observed with this treatment (Figure 27B).
[0037] [Figure 28]Figures 28A-28D show the in vivo antitumor efficacy of the complex in a subcutaneous MCF-7 (breast) tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and when the tumors reached approximately 100 mm3, groups of tumor-bearing mice (n=8) were injected with the composition via the tail vein. Figure 28A shows that untreated mice (squares) showed a more significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the days of injection) after two injections. Figure 28B shows the weight changes of the control and treatment groups. Figure 28C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row), and it is noted that one mouse was tumor-free from day 25 and three mice were tumor-free at the end of the study. Figure 28D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right).
[0038] [Figure 29] Figures 29A-29D show the in vivo antitumor efficacy of the complex in a subcutaneous RT112 (bladder) tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 100 mm3, a group of tumor-bearing mice (n=5) was injected with the composition via the tail vein. Figure 29A shows that untreated mice (squares) showed a more significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the injection date) after three injections. Figure 29B shows the weight change of the control and treated groups. Figure 29C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 29D shows a comparison of tumor weights of the control group (left side) and the stereocomplex-treated group (right side).
[0039] [Diagram 30]Figures 30A-30D show the in vivo antitumor efficacy of the complex in a subcutaneous TT (esophageal) tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 110 mm3, a group of tumor-bearing mice (n=5) was injected with the composition via the tail vein. Figure 30A shows that untreated mice (squares) showed a more significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the days of injection) after three injections. Figure 30B shows the weight change of the control and treated groups. Figure 30C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row), and it is noted that one mouse was tumor-free from day 27 onwards. Figure 30D shows a comparison of the tumor weight of the control group (left) and the stereocomplex-treated group (right).
[0040] [Diagram 31] Figures 31A-31D show the in vivo antitumor efficacy of the complex in a subcutaneous U251 (glioblastoma) tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and when the tumors reached approximately 150 mm3, groups of tumor-bearing mice (n=5) were injected with the composition via the tail vein. Figure 31A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the days of injection) after two injections. Figure 31B shows the weight changes of the control and treated groups. Figure 31C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 31D shows a comparison of tumor weights of the control group (left side) and the stereocomplex-treated group (right side).
[0041] [Diagram 32]Figures 32A-32D show the in vivo antitumor efficacy of the complex in a subcutaneous Caki-1 (kidney) tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 170 mm3, a group of tumor-bearing mice (n=5) was injected with the composition via the tail vein. Figure 32A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the days of injection) after three injections. Figure 32B shows the weight changes of the control and treated groups. Figure 32C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 32D shows a comparison of tumor weights of the control group (left side) and the stereocomplex-treated group (right side).
[0042] [Diagram 33] Figures 33A-33D show the in vivo antitumor efficacy of the complex in a subcutaneous NCI-H522 (non-small cell lung cancer) tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 130 mm3, a group of tumor-bearing mice (n=5) was injected with the composition via the tail vein. Figure 33A shows that untreated mice (squares) showed a more significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the injection date) after two injections. Figure 33B shows the weight change of the control and treatment groups. Figure 33C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row), and it should be noted that three mice were tumor-free at the end of the study. Figure 33D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right).
[0043] [Diagram 34]Figures 34A-34D show the in vivo antitumor efficacy of the complex in a subcutaneous NCI-H226 (non-small cell lung cancer) tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 120 mm3, a group of tumor-bearing mice (n=4) was injected with the composition via the tail vein. Figure 34A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the injection date) after two injections. Figure 34B shows the weight change of the control and treated groups. Figure 34C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 34D shows a comparison of tumor weights of the control group (left side) and the stereocomplex-treated group (right side).
[0044] [Diagram 35] Figures 35A-35D show the in vivo antitumor efficacy of the complex in a subcutaneous Ovcar-3 (ovarian) tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 150 mm3, a group of tumor-bearing mice (n=5) was injected with the composition via the tail vein. Figure 35A shows that untreated mice (squares) showed a more significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume after only one injection. Figure 35B shows the weight change of the control and treated groups. Figure 35C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 35D shows a comparison of tumor weights of the control group (left side) and the stereocomplex-treated group (right side).
[0045] [Diagram 36]Figures 36A-36D show the in vivo antitumor efficacy of the complex in a subcutaneous PC-3 (prostate) tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and when the tumor reached approximately 130 mm3, a group of tumor-bearing mice (n=5) was injected with the composition via the tail vein. Figure 36A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume (arrows indicate the injection date) after three injections. Figure 36B shows the weight change of the control and treated groups. Figure 36C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 36D shows a comparison of tumor weights of the control group (left side) and the stereocomplex-treated group (right side).
[0046] [Figure 37] Figures 37A-37B show the in vivo antitumor efficacy of the complex in a subcutaneous Raji (lymphoma) tumor model by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model. When the tumor volume reached approximately 130 mm3, a group of tumor-bearing mice (n=4) was injected with the complex via the tail vein. After only one injection, three mice were tumor-free on day 15 and all mice were tumor-free from day 22 onwards. Figure 37A shows the tumor size change for the group treated with the complex (circles) versus the control group (squares). Figure 37B shows the photographs of the control mice (top row) and treated mice (bottom row) on day 25 of the study.
[0047] [Figure 38]Figures 38A-38B show blood parameters in nude mice after a single iv injection of the complex. Mice (4 per group) were injected with the complex at a dose of 5 mg / kg DM1 and 32.5 mg / kg DTX by a single iv, then sacrificed on days 3, 7 and 14. Blood samples were collected and analyzed for the following general parameters: white blood cell count (WBC); red blood cell count (RBC); hemoglobin concentration (HGB) and platelet count (PLT). Compared with the control (no injection) labeled day 0, RBC and HGB showed no statistical difference in all studies. Furthermore, lower WBC and PLT were observed on day 3, which all recovered on day 7 and remained normal on day 14.
[0048] [Figure 39] Figure 39 shows clinical chemistry in nude mice after a single iv injection of the complex formulation. Mice (4 per group) were injected with the complex at a single iv dose of 5mg / kg DM1 and 32.5mg / kg DTX, then sacrificed on days 3, 7 and 14. Blood samples were collected and analyzed for the following parameters: alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP), creatinine (CREA) and urea (UREA). Compared with the control (no injection) labeled day 0, ALT and AST were elevated after injection, but recovered on day 14. There was no obvious difference in UREA and CREA, which means there was no nephrotoxicity.
[0049] [Diagram 40]Figures 40 and 41 show histopathological analysis of organs for complex treated group (complex) versus untreated group (control) and prodrug treated group (D-DM1) in CNE (nasopharyngeal) tumor model. Cell suspension was subcutaneously injected into the back of mice to establish tumor model, and when tumors reached approximately 100 mm3, groups of tumor-bearing mice (n=5) were injected weekly for 4 consecutive weeks with the composition via tail vein at doses of 4 mg / kg DM1 for D-DM1 group and 4 mg / kg DM1 with 26 mg / kg DTX for complex group, respectively. After harvesting heart, kidney, spleen, lung and liver, sections were stained with hematoxylin and eosin for observation. Compared with control and D-DM1 treatment, complex treatment did not induce any damage to organs. [Diagram 41] Figures 40 and 41 show histopathological analysis of organs for complex treated group (complex) versus untreated group (control) and prodrug treated group (D-DM1) in CNE (nasopharyngeal) tumor model. Cell suspension was subcutaneously injected into the back of mice to establish tumor model, and when tumors reached approximately 100 mm3, groups of tumor-bearing mice (n=5) were injected weekly for 4 consecutive weeks with the composition via tail vein at doses of 4 mg / kg DM1 for D-DM1 group and 4 mg / kg DM1 with 26 mg / kg DTX for complex group, respectively. After harvesting heart, kidney, spleen, lung and liver, sections were stained with hematoxylin and eosin for observation. Compared with control and D-DM1 treatment, complex treatment did not induce any damage to organs.
[0050] [Diagram 42]Figures 42A-42B show the in vivo antitumor efficacy of glucose-containing complex in a subcutaneous Raji (lymphoma) tumor model by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model. When the tumor volume reached about 130 mm3, a group of tumor-bearing mice (n=4) was injected with the complex via the tail vein. After only one injection, three mice were tumor-free on day 15, and all mice were tumor-free from day 18. Figure 42A shows the tumor size change for the group treated with the complex (circles) versus the control group (squares). Figure 42B shows the photographs of the control mice (top row) and the glucose-containing complex-treated mice (bottom row) on day 25 of the study.
[0051] [Diagram 43] Figure 43 shows stereocomplex pre- and post-treatment PET / CT images of patient 1. By comparison, the intensity of the subcarinal lymph nodes was significantly reduced by treatment.
[0052] [Diagram 44] Figure 44 shows sagittal MR imaging of patient 3 pre- and post-treatment with stereocomplex. Before treatment, sagittal MR of the spine showed multiple large irregularly shaped masses occupying most of the spinal canal from L1 to S1 with minimal visible CSF space. After treatment, MR revealed significant tumor mass reduction in the spinal canal between L1 and S1. Only small residual masses were seen behind L4 and L5 with easily identifiable CSF space and cauda equina nerve fibers.
[0053] [Diagram 45] Figure 45 shows stereocomplex pre- and post-treatment PET / CT images of patient 4. Tumor size was reduced with treatment.
[0054] [Diagram 46]Figure 46 shows stereocomplex pre- and post-treatment PET / CT images of patient 4. Mediastinal, hilar and abdominal aortic lymph node uptake intensity was reduced.
[0055] [Figure 47] Figure 47 shows PET / CT images of patient 4 before and after treatment with stereocomplex. Before treatment, the tumor was found to invade the parietal pleura. However, after treatment, the tumor and the parietal pleura were found to be completely separated. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0056] Detailed Description Before the present materials, articles and / or methods are disclosed and described, it is to be understood that the embodiments described below are not limited to specific compounds, synthetic methods or uses, which, as such, can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
[0057] In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings.
[0058] It must be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an "anticancer agent" includes mixtures of two or more than two such anticancer agents, and the like.
[0059] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where the event or circumstance occurs and cases where it does not occur. For example, the compositions described herein may optionally contain one or more than one targeting group, and the targeting group may or may not be present.
[0060] As used herein, the term "about" is used to provide flexibility to the endpoint numerical range by providing that a given value may be "slightly above" or "slightly below" the endpoint without affecting the desired result. For purposes of this disclosure, "about" refers to a range extending from a 10% lower numerical value to a 10% higher numerical value. For example, if the numerical value is 10, then "about 10" means between 9 and 11, including the endpoints 9 and 11.
[0061] Throughout this specification, unless the context specifically supports otherwise, the word "comprise" or variations such as "comprises" or "comprising" will be understood to mean the inclusion of a specified integer or step, or group of integers or steps, but not the exclusion of any other integers or steps, or group of integers or steps. It is also contemplated that the term "comprise" and variations thereof can be replaced by other transitional phrases such as "consisting of" and "consisting essentially of."
[0062] "Miscible" or "mixture" refers to the combination of two components together in the absence of chemical reaction or physical interaction. The terms "miscible" and "mixture" can also include chemical or physical interaction between any of the components described herein when mixed to produce a composition. The components can be mixed alone in water, in another solvent, or in a combination of solvents.
[0063] The term "solid tumor" as defined herein is an abnormal mass of tissue that does not usually contain cysts or liquid areas. Solid tumors can be benign (not cancer) or malignant (cancer). Various types of solid tumors are named for the type of cells that form the tumor. Examples of solid tumors are sarcomas, carcinomas, and lymphomas.
[0064] The term "subject" as defined herein is any organism in need of cancer treatment and / or prevention. In one embodiment, the subject is a mammal, including but not limited to humans, domestic animals (e.g., dogs, cats, horses), livestock (e.g., cows, pigs) and wild animals.
[0065] The term "treat" as used herein is defined as maintaining or reducing the symptoms of an already existing condition. For example, the compositions described herein are used to treat cancer.
[0066] The term "prevent" as used herein is defined as eliminating or reducing the likelihood of one or more symptoms of a disease or disorder occurring.For example, the compositions described herein can be used to prevent or slow the rate of tumor cell regrowth.
[0067] The term "inhibit" as used herein refers to the ability of the compounds described herein to completely eliminate or reduce activity when compared with the same activity in the absence of the compounds.For example, the compositions described herein can be used to inhibit the growth and / or spread of cancer in the body of a subject.
[0068] A "biodegradable" material is capable of being broken down by bacteria, fungi or other organisms, or by enzymes in the subject's body.
[0069] "Biocompatible" materials are materials that perform their desired function without inducing harmful or deleterious changes to the subject in which they are implanted or to which they are applied locally or systemically. In one aspect, the compositions disclosed herein are biocompatible.
[0070] As used herein, "toxicity" refers to the harmful effect that a substance has on an organism, such as a human or mammal, or on cells within that organism. Compounds or compositions with high toxicity may be deemed unsuitable for use as medical treatment, while compounds or compositions with low toxicity may be acceptable for use as medical treatment. In one aspect, the compounds and compositions disclosed herein exhibit low toxicity.
[0071] The term "alkyl group," as used herein, is a branched or unbranched saturated hydrocarbon group of 1 to 25 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and the like. Examples of longer chain alkyl groups include, but are not limited to, oleate or palmitate groups. A "lower alkyl" group is an alkyl group containing 1 to 6 carbon atoms.
[0072] The term "aryl group" as used herein is any carbon-based aromatic group, including, but not limited to, benzene, naphthalene, and the like. The term "aryl group" also includes "heteroaryl groups," which are defined as aromatic groups having at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorus. Aryl groups can be substituted or unsubstituted. When substituted, aryl groups can be substituted with one or more groups, including, but not limited to, alkyl, alkynyl, alkenyl, aryl, halide, nitro, amino, ester, ketone, aldehyde, hydroxyl, carboxylic acid, or alkoxy.
[0073] The term "alkoxy group" as used herein is defined as RO-, where R is an alkyl or aryl group, as defined herein.
[0074] The term "halogenated group" is any organic group, such as, for example, an alkyl or aryl group, that bears at least one halogen (F, Cl, Br, I).
[0075] References in this specification and in the concluding claims to parts by weight of a particular element in a composition or article represent the weight relationship between the element or component and any other element or component in the composition or article for which the parts by weight are expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight of component Y, X and Y are present in a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are included in the compound. Weight percentages of components are based on the total weight of the formulation or composition in which the component is included, unless specifically stated to the contrary.
[0076] As used herein, a plurality of articles, structural elements, compositional elements, and / or materials may be presented in a common list for convenience. However, these lists should be construed as if each member of the list were individually identified as a separate and unique member. Thus, the individual members of any such list should not be construed as being de facto equivalent to any other member of the same list merely based on their presentation in a common group, unless indicated to the contrary.
[0077] Concentrations, amounts, and other numerical data may be expressed or presented herein in a range format. It should be understood that such range formats are used merely for convenience and brevity, and thus should be interpreted flexibly to include not only the numerical values explicitly recited as limits of the range, but also all of the individual numerical values or subranges subsumed within the range as if each numerical value and subrange were explicitly recited. By way of illustration, a numerical range of "about 1 to about 5" should be interpreted to include not only the explicitly recited value of about 1 to about 5, but also the individual values and subranges within the range recited. Thus, this numerical range includes individual values such as 2, 3, and 4, subranges such as 1 to 3, 2 to 4, 3 to 5, and 1, 2, 3, 4, and 5 individually. The same principle applies to ranges reciting only one numerical value as a minimum or maximum value. Moreover, such interpretation should be applied regardless of the breadth of the range or the characteristics described.
[0078] Disclosed are materials and components that can be used for, can be used in conjunction with, can be used in the preparation of, or are products of the disclosed compositions and methods. These and other materials are disclosed herein, and when combinations, subsets, interactions, groups, etc. of these materials are disclosed, it is understood that each is specifically contemplated and described herein, although specific references to each of the various individual and collective combinations and permutations of these compounds may not be explicitly disclosed. For example, when anticancer drugs are disclosed and discussed, and several different linkers are discussed, each and every possible combination of anticancer drugs and linkers is specifically contemplated, unless specifically indicated to the contrary. For example, when classes of molecules A, B, and C, and classes of molecules D, E, and F, and exemplary combinations of A+D are disclosed, each is individually and collectively contemplated, even if each is not individually listed. Thus, in this example, each of the combinations A+E, A+F, B+D, B+E, B+F, C+D, C+E and C+F is specifically contemplated and should be considered from the disclosure of the exemplary combinations of A, B and C; D, E and F, and A+D. Similarly, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the subgroups of A+E, B+F and C+E are specifically contemplated and should be considered from the disclosure of the exemplary combinations of A, B and C; D, E and F, and A+D. This concept applies to all aspects of the present disclosure, including, but not limited to, steps in the methods of making and using the disclosed compositions. Thus, if there are various additional steps that can be performed with any specific embodiment or combination of embodiments of the disclosed method, each such combination should be considered as specifically contemplated and disclosed. Components in stereocomplexes
[0079] The stereocomplexes described herein are useful for delivering one or more anticancer drugs to a subject.In one embodiment, the stereocomplexes are composed of at least two components, each of which has a hydrophilic group, an isotactic polylactic acid portion, a linker and an anticancer drug.
[0080] In one aspect, the composition comprises the following components: X 1 -Y 1 -L 1 -Z 1 (I) X 2 -Y 2 -L 2 -Z 2 (II) (In the formula, X 1 and X 2 is a hydrophilic group, Y 1 and Y 2 is PDLA or PLLA, L 1 and L 2 is a cleavable linker, Z 1 is an anticancer drug, Z 2 is an anti-cancer agent or imaging agent, and Z 2 If is an anticancer drug, Z 1 and Z 2 are different anticancer drugs, (1) Y 1 If is PDLA, then Y 2 is PLLA, and Y 1 If is PLLA, Y 2 is PDLA, and (2) the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9. Disclosed herein is a stereocomplex having the formula:
[0081] Without wishing to be bound by theory, stereocomplexes are formed when the PDLA and PLLA units present in components (I) and (II) form an extensive three-dimensional network driven by hydrogen bonds.The stereocomplexes described herein have properties such as enhanced tensile strength, Young's modulus and elongation at break compared to either component (I) or component (II) alone.The stereocomplexes have high stability and high resistance to hydrolytic degradation, which eliminates premature release of the drug (i.e., before the stereocomplex reaches its target tissue) and increases the circulation time of the stereocomplex in blood.
[0082] FIG. 1 shows a schematic diagram of an exemplary stereocomplex containing two different drugs based on the stereocomplex formation between PDLA and PLLA. FIG. 2 shows a schematic diagram of an exemplary polymer-conjugated drug for stereocomplex formation. Without wishing to be bound by theory, the hydrophilic elements protrude into the solution while the hydrophobic elements cluster in the particle core (FIG. 2A). An exemplary anticancer drug conjugated to a hydrophobic moiety with a cleavable linker is presented in FIG. 2B. Referring to FIG. 2B, mertansine (DM1) is linked to a carrier with a disulfide bond (D-DM1), and docetaxel (DTX) is linked to a carrier with a hydrazone bond, an ester bond or a disulfide bond (L-DTX).
[0083] Each of the components used to prepare the stereocomplex, as well as methods for making and using it, are described in detail herein. a.Hydrophilic group
[0084] The components used to generate the stereocomplexes disclosed herein contain hydrophilic groups. In one embodiment, X in components (I) and (II) 1 and X 2are different hydrophilic groups. 1 and X 2 are the same hydrophilic group. 1 and X 2 are each a polyalkylene glycol.
[0085] "Polyalkylene glycol" as used herein refers to a condensation polymer of ethylene oxide or propylene oxide and water. Polyalkylene glycols are usually colorless liquids with high molecular weight and are soluble in water and some organic solvents. In one embodiment, the hydrophilic group in the stereocomplexes disclosed herein is a polyalkylene glycol. In another embodiment, the polyalkylene glycol is a polyethylene glycol and / or a polypropylene glycol. In another embodiment, the polyalkylene glycol is a monomethoxypolyethylene glycol. The general structure of a polyalkylene glycol is as follows: [ka] The substitutions in selected polyalkylene glycols are presented in Table 1: [Table 1]
[0086] In a further aspect, the polyalkylene glycol is of sufficiently small molecular weight that the chemical nature of the end group (usually, but not always, hydroxyl) still affects the performance of the polymer. In addition to being hydrophilic, the polyalkylene glycol can modify the viscosity of the stereocomplexes disclosed herein and aid in the formation of emulsions. In another aspect, the polyalkylene glycol is biocompatible and / or biodegradable. In yet another aspect, the polyalkylene glycol and / or other hydrophilic groups used herein are non-toxic.
[0087] In one embodiment, X in components (I) and (II) 1 and X 2 is a polyalkylene glycol, X 1 and X 2 has a molecular weight of about 1,000 Da to about 5,000 Da, or 1,500 Da to 4,500 Da, or 2,000 Da to 4,000 Da, or has a molecular weight of about 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or about 5,000 Da, any of which can be the lower and upper endpoints of a range (e.g., 2,000 Da to 4,000 Da).
[0088] In another embodiment, X in components (I) and (II) of the stereocomplex disclosed herein 1 and X 2 are monomethoxypolyethylene glycols having a molecular weight of about 1,000 to about 5,000 Da, or 1,500 Da to 4,500 Da, or 2,000 Da to 4,000 Da, respectively, or having a molecular weight of about 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or about 5,000 Da, either of which can be the lower and upper end points of a range (e.g., 2,000 Da to 4,000 Da). In one embodiment, X in components (I) and (II) of the stereocomplex disclosed herein 1 and X 2 are each monomethoxypolyethylene glycols having the same molecular weight. b. PDLA / PLLA
[0089] Polylactic acid is a polyester derived from lactic acid. The polyester is composed of lactic acid units as illustrated in the structure below, where m indicates the number of lactic acid units. Lactic acid units are represented by an asterisk ( * ), where m is the number of lactic acid units: [ka]
[0090] Polylactic acid polymerization can be initiated from D or L lactic acid, or a mixture thereof, or lactide, a cyclic diester. The properties of polylactic acid can be fine-tuned by controlling the ratio of D to L enantiomers used in the polymerization, and polylactic acid polymers can also be synthesized using only D or only L starting materials rather than a mixture of the two. Polylactic acid prepared exclusively from D starting materials is referred to as poly-D-lactide (PDLA) (i.e., composed exclusively of D-lactic acid units), whereas polylactic acid prepared exclusively from L starting materials is poly-L-lactide (or PLLA) (i.e., composed exclusively of L-lactic acid units).
[0091] As used herein, D-lactic acid units or L-lactic acid units refer to monomeric units within the polylactic acid polymers described herein, as shown in Table 2, where the D-lactic acid units are derived from a D-lactic acid or D-lactide starting material and the L-lactic acid units are derived from an L-lactic acid or L-lactide starting material: [Table 2]
[0092] The polylactic acid in components (I) and (II) is Y 1 and Y 2 and Y 1 If is PDLA, then Y 2 is PLLA or, alternatively, Y 1 If is PLLA, Y 2 is PDLA.
[0093] In one embodiment, the ratio of the total number of D-lactic acid units in the stereocomplex to the number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9. In another embodiment, the ratio of the total number of D-lactic acid units to the number of L-lactic acid units is 0.9:1.1, 0.95:1.05, 1:1, 1.05:0.95 or 1.1:0.9. In one embodiment, the ratio of the total number of D-lactic acid units to the number of L-lactic acid units is close to 1:1. In other words, in some embodiments, the total number of D-lactic acid units and L-lactic acid units in the stereocomplex is approximately equal.
[0094] PDLA and PLLA are present in components (I) and (II). However, as discussed in more detail below, additional components can be used to prepare the stereocomplexes herein that contain PDLA or PLLA. These components add to the total number of D-lactic acid units or L-lactic acid units present in the stereocomplex.
[0095] In one embodiment, the PDLA and PLLA present in components (I) and (II) have a molecular weight of about 700 Da to about 5,000 Da, or about 750 Da to 4000 Da, or about 1,000 Da to about 3,000 Da. Further, in this embodiment, the PDLA and PLLA have a molecular weight of about 700 Da, 750 Da, 800 Da, 900 Da, 1,000 Da, 1,250 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or 5,000 Da, any of which may be the lower and upper end points of the range (e.g., 1,000 Da to 3,000 Da). In another embodiment, the PDLA and PLLA present in components (I) and (II) have equal or nearly equal molecular weights.
[0096] In another embodiment, the number of D-lactic acid units present in PDLA and L-lactic acid units present in PLLA in components (I) and (II) is 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100, any value being the lower and upper endpoints of a range (e.g., 10 to 60). In another embodiment, the PDLA and PLLA present in components (I) and (II), respectively, have the same number of D-lactic acid units and L-lactic acid units.
[0097] The hydrophilic groups in components (I) and (II) are covalently attached to PDLA or PLLA. In one embodiment, when the hydrophilic group is monomethoxypolyethylene glycol, the terminal hydroxyl group can react with the terminal carboxyl group of PDLA or PLLA to form a new ester. Exemplary methods for attaching hydrophilic groups to PDLA or PLLA are provided in the examples. C. Cleavable linker
[0098] In one embodiment, the stereocomplex disclosed herein comprises a cleavable linker.The cleavable linker comprises at least one cleavable group, so that the anticancer drug is released when cleaved.The cleavable group can be cleaved, for example, by enzyme, hydrolysis, or pH change.
[0099] In one embodiment, the L present in components (I) and (I) 1 and L 2 are different cleavable linkers. Further, in this embodiment, L 1 and L 2can exhibit different cleavage rates (e.g., hydrolysis, enzymes, pH) due to the presence of different cleavable groups, and thus release the linked anticancer drug at various controlled rates. In one aspect, the selection of the cleavable linker and the rate of hydrolytic degradation of the linker can reduce the required concentration of the anticancer drug or enhance the synergistic effect of the anticancer drug present in the stereocomplex. Thus, L 1 and L 2 may be selected to achieve sequential or simultaneous release of two different anticancer drugs. 1 and L 2 is the same cleavable linker.
[0100] In one embodiment, L 1 and L 2 independently comprise a cleavable group, including, but not limited to, a disulfide group, an ester group, a hydrazone group, an acetal group, an imine group, a β-thiopropionate group, an amide group, or any combination thereof. The cleavable linker molecule can comprise one or more of these groups. The cleavable linker can also comprise additional functional groups, such that the cleavable linker can be covalently attached to PDLA or PLLA. In one embodiment, the cleavable linker comprises a functional group that can react with the terminal hydroxyl group of PDLA or PLLA to generate a new covalent bond. For example, the cleavable linker can comprise a carboxyl group (e.g., carboxylic acid, ester, anhydride) that reacts with the hydroxyl group of PDLA or PLLA. Exemplary methods for attaching cleavable linkers to PDLA or PLLA are provided in the Examples and Figures herein. Disulfide groups
[0101] As used herein, a disulfide group is a functional group having the structure (-SS-). Upon cleavage of the disulfide group, the anticancer drug is released. In one embodiment, the L of the stereocomplex disclosed herein is 1 Or L 2 , or L 1and L 2 Both of the linkers contain disulfide groups. Without wishing to be bound by theory, disulfide groups are sensitive to glutathione redox. Glutathione (GSH) in cancer cells is involved in regulating the oncogenic mechanism; sensitivity to cytotoxic drugs, ionizing radiation and some cytokines; DNA synthesis; and cell proliferation and death. GSH can cleave disulfide bonds to release anticancer drugs present in stereocomplexes to generate the corresponding thiols. Representative linkers with disulfide groups are presented herein. Ester group
[0102] As used herein, an ester group is a functional group having the following structure: [ka]
[0103] In one embodiment, the L of the stereocomplex disclosed herein 1 Or L 2 , or L 1 and L 2 Both of the above-mentioned linkers contain an ester group. Upon cleavage of the ester group, the anticancer drug is released. Exemplary methods for preparing and using cleavable linkers having an ester group are provided in the Examples and Figures herein. Hydrazone group
[0104] As used herein, a hydrazone group is a functional group having the following structure, where R and R' can be the same or different: [ka]
[0105] In one embodiment, the L of the stereocomplex disclosed herein 1 Or L 2 , or L 1 and L 2Both of the above-mentioned linkers contain a hydrazone group. Upon cleavage of the hydrazone group, the anticancer drug is released. Exemplary methods for preparing and using cleavable linkers having a hydrazone group are provided in the Examples and Figures herein. Acetal Group
[0106] As used herein, an acetal group is a functional group having the following structure, where R, R′, and R″ can be the same or different: [ka]
[0107] In one embodiment, the L of the stereocomplex disclosed herein 1 Or L 2 , or L 1 and L 2 Both contain an acetal group, upon cleavage of the acetal group, the anticancer drug is released. Imine group
[0108] As used herein, an imine group is a functional group having the following structure: [ka]
[0109] In one embodiment, the L of the stereocomplex disclosed herein 1 Or L 2 , or L 1 and L 2 Both contain an imine group, upon cleavage of the imine group, the anticancer drug is released. β-thiopropionate group
[0110] As used herein, a β-thiopropionate group is a functional group having the following structure, where R and R′ can be the same or different: [ka]
[0111] In one embodiment, the L of the stereocomplex disclosed herein 1 Or L 2 , or L 1 and L 2 Both contain a β-thiopropionate group. Upon cleavage of the β-thiopropionate group, the anticancer drug is released. Amide group
[0112] As used herein, an amide group is a functional group having the following structure: [ka]
[0113] In one embodiment, the L of the stereocomplex disclosed herein 1 Or L 2 , or L 1 and L 2 Both contain an amide group. Upon cleavage of the amide group, the anticancer drug is released. D. Anticancer drugs
[0114] In one embodiment, the stereocomplexes described herein include two or more anti-cancer drugs. As used herein, an "anti-cancer drug" is a compound used to kill cancer cells in a subject's body, slow the growth of cancer in a subject, prevent cancer from spreading in a subject, or prevent a surgically removed tumor from returning. Anti-cancer drugs can work in a variety of ways, including, but not limited to, by alkylating DNA (which can prevent helicalization and recognition by DNA replication enzymes), by interfering with the production of DNA, by interfering with the production of proteins in cancer cells, by preventing cancer cells from dividing, or by slowing the growth of hormone-dependent cancers. The anti-cancer drug is covalently attached to a cleavable linker.
[0115] The relative amounts of each anticancer drug present in the stereocomplex can be varied to achieve additive and / or synergistic therapeutic effects with a particular type of cancer, this feature of the stereocomplex is described in more detail below.
[0116] In one embodiment, the anticancer agent is paclitaxel, doxorubicin, gemcitabine, cisplatin, methotrexate, 5-fluorouricil, betulinic acid, amphotericin B, diazepam, nystatin, propofol, testosterone, docetaxel, maytansinoid, PD-1 inhibitor, PD-L1 inhibitor, protein kinase inhibitor, P-glycoprotein inhibitor, autophagy inhibitor, PARP inhibitor, aromatase inhibitor, monoclonal antibody, photosensitizer, radiosensitizer, interleukin, antiandrogen, or any combination thereof. In one embodiment, when the anticancer agent is a maytansinoid, the anticancer agent can be ansamitocin, mertansine (DM1), ravtansine, or another maytansinoid. In a further embodiment, the anticancer agent can be classified into more than one of the above categories simultaneously. For example, the aromatase inhibitor can be an anti-androgen and the PD-1 inhibitor can be a monoclonal antibody.
[0117] In one embodiment, the anti-cancer agent is a PD-1 inhibitor or a PD-L1 inhibitor. PD-1 inhibitors and PD-L1 inhibitors are immune checkpoint inhibitors that inhibit the association of programmed cell death ligand 1 (PD-L1) with programmed cell death protein 1 (PD-1). This protein-ligand interaction is involved in suppressing the immune system in certain types of cancer. In one embodiment, the compositions disclosed herein include a PD-1 and / or PD-L1 inhibitor. In a further embodiment, the PD-1 inhibitor can be pembrolizumab, nivolumab, pidilizumab, AMP-224, AMP-514, or PDR001. In yet another embodiment, the PD-L1 inhibitor can be atezolizumab, avelumab, durvalumab, or BMS0936559. Without wishing to be bound by theory, when PD-L1 on a cancer cell interacts with PD-1 on a T cell, the functional signal of the T cell is reduced, thereby preventing the immune system from attacking the tumor cell. Thus, blocking this interaction allows the immune system to target tumor cells. In one embodiment, advanced melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, Hodgkin's lymphoma and other cancers can be treated with PD-1 and PD-L1 inhibitors.
[0118] In one embodiment, the anti-cancer agent is a monoclonal antibody. In monoclonal antibody therapy, the monoclonal antibody binds monospecifically to target cells and / or proteins and stimulates the subject's immune system to attack those cells. In some embodiments, the monoclonal antibody therapy is used in conjunction with radiation therapy. In one embodiment, the compositions disclosed herein include a monoclonal antibody. The monoclonal antibody can be murine (suffix -omab), chimeric (suffix -ximab), humanized (suffix -zumab) or human (suffix -umab). In one embodiment, the monoclonal antibody is selected from the group consisting of ramucirumab, 3F8, 8H9, abagovomab, avituzumab, adalimumab, afutuzumab, alacizumab pegol, amatuximab, anatumomab mafenatox, andecaliximab, anetumab ravtansine, apolizumab, arcitumomab, asclinbacumab, atezolizumab, avelumab, azintuxizumab vedotin, bavituximab, BCD-100, vera. Intamabu mafodotin, belimumab, bemarituzumab, besilesomab, bevacizumab, bivatuzumab mertansine, brentuximab vedotin, brontiximab, cabilalizumab, camidanlumab tesirin, camrelizumab, cantuzumab mertansine, cantuzumab vedotin, carotuximab, cantumaxomab, cBR96-doxorubicin immunoconjugate, semi Primab, sergituzumab amnaleukin, cetrelimab, cetuximab, civisatamab, sitatuzumab bogatox, cixutumumab, clivatuzumab tetraxetan, codrituzumab, cofetuzumab peridotin, cortuximab lavtansine, conatumumab, cusatuzumab, dacetuzumab, darotuzumab, daratumumab, demcizumab, denituzumab mafodotin, depatutuzumab mafodotin, delrotuzumab Ximab-biotin, Detumomab, Dinutuximab, Drozitumab, DS-8201, Durigotuzumab, Durvalumab, Dusitgitumab, Duvortuximab, Eclomeximab, Edrecolomab, Elgemtuzumab, Elotuzumab, Emactuzumab, Emibetuzumab, Enapotomab vedotin, Enavatuzumab, Enfortumab vedotin, Enoblituzumab, Ensituximab,Epratuzumab, Ertumaxomab, Etaracizumab, Faricimab, Farletuzumab, FBTA05, Ficlatuzumab, Figitumumab, Franvotumab, Flotetuzumab, Futuximab, Galiximab, Gancotamab, Ganitumab, Gatipotuzumab, Gemtuzumab ozogamicin, Girentuximab, Glembatumumab vedotin, IBI308, Ibritumomab tiuxetan, Icrucumab, Iradatuzumab vedotin, IMAB362, Imalumab, Imgatuzumab, Indusatuzumab vedotin, Inevitizumab , intetumumab, ipilimumab, iratumumab, isatuximab, istiratumab, labetuzumab, lacunotuzumab, radazilatuzumab vedotin, lenzilumab, lexatumumab, rifastuzumab vedotin, loncastuzumab tesirin, rosatuximab vedotin, rilotumab satetraxetan, lintuzumab, lirilumab, lorvotuzumab mertansine, lucatumumab, rumiliximab, lumuletuzumab, MABp1, mapatumumab, margetuximab, matuzumab, milatuzumab, mirvetuximab soravtansine, mitumomab, modotuximab , mogamulizumab, monalizumab, mosunetuzumab, moxetumomab pasudotox, nacolomab butafenatox, naptumomab estafenatox, narutumab, navicixizumab, naxitumab, necitumumab, nesbacumab, nimotuzumab, nivolumab, nofetumomab merpentan, obinutuzumab, ocaratuzumab, ofatumumab, olaratumab, oleculab, onartuzumab, ontuxizumab, oportuzumab monatox, oregovomab, otlertuzumab, pamrevrumab, panitumumab, pancomab, palsatuzumab, pasotuki Cizumab, Patritumab, PDR001, Pembrolizumab, Pemtumomab, Pertuzumab, Pidilizumab, Pinatuzumab vedotin, Polatuzumab vedotin, Pritumumab, Racotumomab, Ladolezumab, Ramucirumab, Rilotumumab, Rituximab, Lobatumumab, Rosumantuzumab, Robalpituzumab Tecilline, Sacituzumab govitecan, Samalizumab, Samlotumab vedotin, Seribantumab, Sibrotuzumab, SGN-CD19A, Siltuximab, Siltratuzumab vedotin, Sofituzumab vedotin, Solitumab,Spartalizumab, tabalumab, tacatuzumab tetraextan, tapitumumab paptox, tarexitumab, taborimab, telisotuzumab vedotin, tenatumomab, tepotizimab, tetulomab, TGN1412, tigatuzumab, timigtuzumab, tilagotumab, tislezulizumab, tisotuzumab vedotin, TNX-650, tobetumab, trastuzumab, trastuzumab emtansine, TRBS07, tremelimumab, These are tucotuzumab celmoleukin, ublituximab, urocupulumab, urelumab, utomilumab, vadastuximab butarilin, bundletuzumab vedotin, vanticutuzumab, vanucizumab, valisacumab, varlilumab, veltuzumab, besencumab, volociximab, bonlerolizumab, borsetuzumab mafodotin, votumumab, XMAB-5574, zalutumumab, zatuximab, xenoctuzumab, zolbetuximab, or tositumomab. In another aspect, the monoclonal antibody is intended to be used in the treatment of advanced malignancies and lymphomas, such as non-Hodgkin's lymphoma, and in the treatment of cancers including neuroblastoma, sarcoma, metastatic brain cancer, ovarian cancer, prostate cancer, breast cancer (including triple negative breast cancer), lymphoma, non-small cell lung cancer, gastric cancer, gastroesophageal junction adenocarcinoma, hematological cancers, melanoma, squamous cell carcinoma, Hodgkin's lymphoma, anaplastic large cell lymphoma, pancreatic cancer, acute lymphoblastic leukemia, acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer, angiosarcoma, head and neck cancer, ovarian cancer, solid tumors, multiple myeloma, glioblastoma, testicular cancer, B cell malignancies, urothelial cancer, chronic lymphocytic leukemia, adrenocortical carcinoma, It can be used to treat adenocortical carcinoma, acute myeloid leukemia, renal clear cell carcinoma, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, small cell lung cancer, hairy cell leukemia, renal cell carcinoma, nasopharyngeal carcinoma, glioma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma and other cancers.
[0119] In one embodiment, the anti-cancer agent is a photosensitizer. Photosensitizers are used in conjunction with light and molecular oxygen to induce cell death. In one embodiment, the compositions disclosed herein include a photosensitizer. Without wishing to be bound by theory, a first photosensitizer is administered in the absence of light until the photosensitizer reaches a critical concentration in the tissue to be treated. Following this, the photosensitizer is activated by exposure to a level of light sufficient to activate the photosensitizer while minimizing damage to nearby healthy tissue. In further embodiments, malignant cancers of the head and neck, lung, bladder and skin (including Kaposi's sarcoma and non-melanoma skin cancer of the skin), metastatic breast cancer, cancer of the gastrointestinal tract, and bladder cancer may be particularly sensitive to photosensitizers. In one embodiment, the photosensitizer can be a porphyrin, a chlorine, or a dye. In another embodiment, the photosensitizer is 5-aminolevulinic acid (Levulan), silicon phthalocyanine Pc4, naphthalocyanine, metallo-naphthalocyanine, purpurins (IV), copper octaethylbenzochlorin, purpurin zinc (II), m-tetrahydroxyphenylchlorin, mono-L-aspartyl chlorin e6, Allumera, Photofrin, Visdyne (verteporfin), Foscan, Metvix, Hexvix, Cysview, Laserphyrin, Antrin, Photochlor, Photosens, Photrex, Purlytin, Lutex, Lumacan, Cevira, Visonac, BF-200ALA, Amphipinez, azadipyrromethene, zinc phthalocyanine, or another photosensitizer.
[0120] In one embodiment, the anticancer agent is a protein kinase inhibitor.Protein kinase inhibitors block the action of one or more protein kinases.Protein kinases may be overexpressed in certain types of cancer.In some embodiments, the compositions disclosed herein comprise one or more protein kinase inhibitors. In further aspects, the protein kinase inhibitor can be afatanib, axitinib, bosutinib, cetuximab, cobimetinib, crizotinib, cabozanitinib, dasatinib, entrectinib, erlotinib, fostamatinib, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, mubritinib, nilotinib, pazopanib, pegaptanib, ruxolitinib, sorafenib, sunitinib, SU6656, vandetanib, vemurafenib, or another protein kinase inhibitor. In some aspects, protein kinase inhibitors are particularly useful against non-small cell lung cancer, renal cell carcinoma, chronic myeloid leukemia, advanced melanoma, metastatic medullary thyroid carcinoma, neruoblastoma, colorectal cancer, breast cancer, thyroid cancer, renal cancer, myelofibrosis, renal cell carcinoma, or gastrointestinal stromal tumors.
[0121] In one embodiment, the anti-cancer drug can be a p-glycoprotein inhibitor. P-glycoprotein is a promiscuous drug efflux pump, which can reduce the bioavailability of drugs at tumor sites. Without wishing to be bound by theory, p-glycoprotein inhibitors can enhance the intracellular accumulation of anti-cancer drugs. In one embodiment, this is achieved by binding to the p-glycoprotein transporter, which can inhibit the transmembrane transport of anti-cancer drugs. Inhibition of transmembrane transport can result in an increase in the intracellular concentration of anti-cancer drugs, which can ultimately enhance their cytotoxicity. In a further embodiment, the p-glycoprotein inhibitor is selected from the group consisting of verapamil, cyclosporine, tamoxifen, calmodulin antagonists, dexverapamil, dexniguldipine, valspodar (PSC833), biliquidar (VX-710), tariquidar (XR9576), zosuquidar (LY335979), laniquidar (R101933), elacridar (GF120918), timcodar (VX-853), taxifolin, naringenin, diosmin, Quercetin, diltiazem, bepridil, nicardipine, nifedipine, felodipine, isradipine, trifluoperazine, clopenthixol, trifluopromazine, flupentixol, emopamil, gallopamil, Ro11-2933, amiodarone, clarithromycin, colchicine, erythromycin, lansoprazole, omeprazole, another proton pump inhibitor, paroxetine, sertraline, quinidine, or any combination thereof. In one embodiment, p-glycoprotein inhibitors are particularly effective in treating drug-resistant cancers, including as part of a combination therapy.
[0122] In one embodiment, the anticancer agent is an autophagy inhibitor. Autophagy, as used herein, is a mechanism of intracellular degradation that depends on lysosomes. Autophagy involves multiple proteins, including some protein kinases. Autophagy inhibitors can target early stages of autophagy (i.e., pathways involved in the initial steps of core autophagy machinery) or late stages (i.e., lysosomal function). In one embodiment, the compositions disclosed herein comprise one or more autophagy inhibitors. In further embodiments, the autophagy inhibitor can be 3-methyladenine, wortmannin, LY294002, PT210, GSK-2126548, spautin-1, SAR405, compound 31, VPS34-IN1, PIK-III, compound 6, MRT68921, SBI-0206965, pepstatin A, E64d, bafilomycin A1, clomipramine, lucanthone, chloroquine, hydroxychloroquine, Lys05, ARN5187, compound 30, or another autophagy inhibitor. In further embodiments, the autophagy inhibitor can be useful for treating non-small cell lung cancer, chronic myeloid leukemia, metastatic prostate cancer, castration-resistant prostate cancer, metastatic colorectal cancer, breast cancer, brain metastases, recurrent and refractory multiple myeloma, glioblastoma multiforme, and other cancers.
[0123] In one embodiment, the anticancer drug is a radiosensitizer. Radiosensitizers make tumor cells more sensitive to radiation therapy. In one embodiment, the compositions disclosed herein include one or more radiosensitizers. In one embodiment, the radiosensitizer is fluoropyrimidine, gemcitabine, platinum analogs (such as cisplatin), NBTXR3, Nimoral, trans sodium crocetinate, NVX-108, misonidazole, metronidazole, tirapazamine or another radiosensitizer. Without wishing to be bound by theory, radiosensitizers interfere with the regulation of cell cycle checkpoints in tumor cells, especially those caused by DNA damage caused by radiation therapy. Some radiosensitizers may crosslink DNA strands and exacerbate the DNA damage caused by radiation therapy. In one embodiment, the radiosensitizers may be particularly useful in treating soft tissue sarcomas of the extremities and trunk wall, hepatocellular carcinoma, prostate cancer, oral squamous cell carcinoma, squamous cell carcinoma of the head and neck, and glioblastoma.
[0124] In one embodiment, the anticancer agent is a PARP inhibitor. PARP inhibitors act against the enzyme poly ADP ribose polymerase. In one embodiment, the compositions disclosed herein comprise one or more PARP inhibitors. Without wishing to be bound by theory, PARP inhibitors can block PARP activity, prevent DNA damage repair, and also localize PARP protein at the site of DNA damage, thereby blocking DNA replication and thus being cytotoxic. In one embodiment, PARP inhibitors are effective against recurrent platinum-sensitive ovarian cancer, tumors caused by BRCA1, BRCA2 or PALB2 mutations, PTEN-deficient tumors (e.g., certain prostate cancers), fast-growing tumors with low oxygen levels, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, lung squamous cell carcinoma, hematological malignancies, advanced or recurrent solid tumors, non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, metastatic breast and ovarian cancer, and metastatic melanoma. In one embodiment, the PARP inhibitor is MK-4827 (also known as niraparib), rucaparib, iniparib, talazoparib, olaparib, veliparib, CEP9722, E7016, BGB2-290, 3-aminobenzamide, or another PARP inhibitor.
[0125] In one embodiment, the anti-cancer agent is an interleukin. Interleukins are cytokines or signaling molecules that are usually expressed by white blood cells. In some embodiments, exogenously synthesized interleukins can be used as cancer treatment. In one embodiment, the compositions disclosed herein include one or more interleukins. In further embodiments, the interleukin can be PROLEUKIN® (also known as IL-2 and aldesleukin) or another interleukin. Without wishing to be bound by theory, interleukins can help promote the growth of killer T cells and other immune cells as they are associated with emerging tumor cells, thereby enhancing the function of the subject's immune system. In another embodiment, interleukins can be effective against kidney cancer and melanoma.
[0126] In one embodiment, the anticancer agent is an mTOR inhibitor. An mTOR inhibitor is a drug that inhibits the mechanistic target of rapamycin. mTOR is a serine / threonine specific protein kinase and is important for the regulation of metabolism, growth and cell proliferation. In one embodiment, the composition disclosed herein comprises one or more mTOR inhibitors. In further embodiments, the mTOR inhibitor can be rapamycin, sirolimus, temsirolimus, everolimus, ridaforolimus, deforolimus, dactolisib, sapanisertib, AZD8055, AZD2014 or another mTOR inhibitor. Without wishing to be bound by theory, mTOR inhibitors act on T cell proliferation and proliferative responses induced by various cytokines, including processes related to tumor angiogenesis. In one embodiment, certain mTOR inhibitors can be primarily effective against tumors with specific genetic determinants or mutations. mTOR inhibitors may be particularly effective against renal cell carcinoma, subependymal giant cell astrocytoma, progressive neuroendocrine tumors of pancreatic origin, or progressive breast cancer. In another embodiment, mTOR inhibitors may be used as monotherapy for disease stabilization or as part of combination therapy for many cancer types.
[0127] In one embodiment, the anti-cancer agent is an aromatase inhibitor. Aromatase inhibitors are useful for the treatment and prevention of breast and ovarian cancer, especially in postmenopausal women, high-risk women, and women with hormone-sensitive tumors. In one embodiment, the compositions disclosed herein include one or more aromatase inhibitors. Without wishing to be bound by theory, aromatase inhibitors block the conversion of various precursors, including androstenedione and testosterone. In one embodiment, the aromatase inhibitor is an irreversible steroid inhibitor, which can act by forming a permanent bond with aromatase enzyme. In another embodiment, the aromatase inhibitor is a non-steroid inhibitor, which reversibly competes with the substrate for aromatase enzyme. In yet another embodiment, the specific mechanism of action of aromatase inhibitors may be unknown. In one aspect, the aromatase inhibitor can be aminoglutethimide, testolactone, anastrozole, letrozole, exemestane, vorozole, formestane, fadrozole, 1,4,6-androstatriene-3,17-dione, 4-androstene-3,6,17-trione, or another aromatase inhibitor.
[0128] In one embodiment, the anticancer agent is an antiandrogen.Antiandrogens or androgen synthesis inhibitors prevent the biosynthesis of androgen hormones.In one embodiment, the compositions disclosed herein include one or more antiandrogens.Without wishing to be bound by theory, antiandrogens can act at a variety of different steps in the androgen synthesis pathway, including but not limited to inhibiting the conversion of cholesterol to steroid hormone precursors or inhibiting the conversion of pregnane steroids to androgens.In one embodiment, the antiandrogen can be aminoglutethimide (which also acts as an aromatase inhibitor), ketoconazole, abiraterone acetate, ceviteronel, or another antiandrogen. e. Imaging agents
[0129] The stereocomplex disclosed herein may include one or more imaging agents.As used herein, "imaging agent" refers to a compound or composition that enhances contrast, visibility or other properties during medical imaging procedures, such as, for example, X-ray, computed tomography and single photon emission computed tomography, ultrasound, MRI (magnetic resonance imaging), nuclear medicine procedures (including positron emission tomography and related techniques), optical imaging, near infrared imaging, angiography, venography, endoscopy, voiding cystourethrogram, hysterosalpingogram, intravenous urography or other medical imaging procedures.Imaging agents are generally non-toxic and stable in vivo.An ideal imaging agent should be rapidly cleared from the bloodstream, bind to and accumulate in specific target tissues.
[0130] In one embodiment, Z in component (II) 2 is an imaging agent, which is covalently attached to component (II). In another embodiment, the stereocomplex comprises the following components: X 1 -Y 1 -L 1 -Z 1 (I) X 2 -Y 2 -L 2 -Z 2 (II) (In the formula, X 1 and X 2 is a hydrophilic group, Y 1 and Y 2 is PDLA or PLLA, L 1 and L 2 is a cleavable linker, Z 1 is an anticancer drug, Z 2 is an imaging agent, (1) Y 1 If is PDLA, then Y 2 is PLLA, and Y 1 If is PLLA, Y 2is PDLA, and (2) the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9. It consists of:
[0131] In another embodiment, the stereocomplex comprises the following components: X 1 -Y 1 -L 1 -Z 1 (I) X 2 -Y 2 -L 2 -Z 2 (II) X 5 -Y 5 -L 5 -Z 5 (IX) (In the formula, X 1 , X 2 and X 5 is a hydrophilic group, Y 1 , Y 2 and Y 5 is PDLA or PLLA, L 1 , L 2 and L 5 is a cleavable linker, Z 1 and Z 5 is a different anticancer drug, Z 2 is an imaging agent, and the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9. It consists of:
[0132] In one embodiment, the imaging agent comprises: 11 CL-methyl-methionine, 18 F-fluorodeoxyglucose, 18 F - sodium fluoride, 18 F fluorocholine, 18 F Desmethoxyfalipride, 67 Ga-Ga 3+ , 68 Ga-dotatoc,68 Ga-PSMA, 111 In-Diethylenetriaminepentaacetic acid, 111 In-white blood cells, 111 In-platelets, 111 In-Penetreotide, 111 In-Octreotide, 123 I-iodide, 123 Io-iodohiplate, 123 Im-iodobenzylguanidine, 123 I-FP-CIT, 125 I-fibrinogen, 131 I-iodide, 131 Im-iodobenzylguanidine, 81 Kr m -gas, 81 Kr m -aqueous solution, 13 N-ammonia, 15 O-water, 75 Se-selenolcholesterol, 75 Se-seleno-25-homo-tauro-cholate, 120 Tl-Tl + , 133 Xe-gas, 133 Xe (in isotonic sodium chloride solution), 99 Tc m -Pertechnetate, containing macroaggregates or microspheres 99 Tc m - human albumin, 99 Tc m phosphonates and / or phosphates, 99 Tc m -diethylenetriaminepentaacetic acid, 99 Tc m -dimercaptosuccinic acid, 99 Tc m -colloid, 99 Tc m -Hepatic iminodiacetic acid, 99 Tc m whole red blood cells, 99 Tc m -Mercaptoacetyltriglycine, containing Examethazime-labeled leukocytes 99 Tc m Examethadim, 99 Tcm Sesta-methoxyisobutylisonitrile, 99 Tc m IMMU-MN3 mouse Fab'-SH anti-granulocyte monoclonal antibody fragment; 99 Tc m -Technegas, 99 Tc m Human immunoglobulin, 99 Tc m - tetrofosmin, 99 Tc m -ethyl cysteinate dimer, or another radiopharmaceutical. In yet another embodiment, the radiopharmaceutical is a metal ion with a chelator.
[0133] In another embodiment, the imaging agent can be a radiological contrast agent. In a further embodiment, the imaging agent can be an iodine contrast agent, e.g., ionic, such as diatrizoate, metrizoate, iothalamate, or ioxaglate, or non-ionic, e.g., iopamidol, iohexol, ioxilan, iopromide, iodixanol, ioversol, or another iodine contrast agent. In a further embodiment, the imaging agent can be based on barium sulfate, or a gadolinium-based contrast agent, e.g., gadoterate, gadodiamide, gadobenate, gadopentetate, gadoteridol, gadofosveset, gadoversetamide, gadoxetate, gadobutrol, or another gadolinium chelator.
[0134] In yet another embodiment, the imaging agent can be an optical imaging agent useful for fluorescence, chromoendoscopy or another optical imaging technique. In a further embodiment, the imaging agent can be methylene blue, indigo carmine or another non-specific dye. In an alternative embodiment, the imaging agent can be a fluorophore, such as, for example, fluorescein isothiocyanate, indocyanine green, rosamine, BODIPY (boron-dipyrromethane) derivatives, chalcone, xanthone, oxazole yellow, thiazole orange, fluorescein, luciferin, Texas red, squaraine, porphyrin, phthalocyanine, polymethine cyanine dyes (e.g., Cy3, Cy5, Cy5.5, Cy7), Alexa fluor, or a precursor molecule (e.g., 5-aminolevulinic acid) for a fluorescent metabolite (e.g., protoporphyrin X). In one embodiment, the fluorophore can be a metal chelator.
[0135] "Quantum dots" as referred to herein are nanoparticles made of semiconductor materials. Quantum dots have different properties than larger semiconductor particles and materials. These properties can be tuned by the size and shape of the particle. Quantum dots can be useful for medical imaging. In one aspect, imaging agents useful herein can include quantum dots that can be uncoated or can be coated or encapsulated by polymers or hydrogels. In one aspect, quantum dots have high extinction coefficients and are useful for fluorescence-based imaging techniques. Additional Components
[0136] In addition to components (I) and (II), additional components can be used to generate the stereocomplex. In one aspect, the stereocomplexes disclosed herein can be used to perform functions such as maintaining the formation of stereocomplexes having different ratios of anticancer drugs, or to incorporate one or more additional anticancer drugs (Z 1 and Z 2The stereocomplex may contain one or more additional components to confer a specific molecular identity (other than the molecular identity) to the stereocomplex, to target it to a particular cell or tissue type, or to exert another function. A. Anticancer drug ratio modifier
[0137] In one embodiment, additional component (VII): X 3 -Y 3 (VII) (In the formula, X 3 is a hydrophilic group as previously described, and Y 3 is PDLA or PLLA).
[0138] In certain embodiments, two different anticancer drugs (Z 1 and Z 2 In cases where a 1:1 ratio of Z is desired, equimolar amounts of components (I) and (II) may be used. However, in certain embodiments, 1 and Z 2 It is desirable to vary the relative amounts of one anti-cancer agent to a second anti-cancer agent. The desired ratio of one anti-cancer agent to a second anti-cancer agent depends on the type of cancer being treated in the subject.
[0139] The inclusion of component (VII) allows modification of the molar ratio of anticancer drugs present in the stereocomplex while maintaining the optimal ratio of D- and L-lactic acid units for the formation of the stereocomplex. As an example, the following scheme shows the formation of a stereocomplex of Z 1 :Z 2 is presented to demonstrate how to generate a stereo complex with a 2:1 ratio. X 1 -PDLA-L 1 -Z 1 (I) (1 molar equivalent) X 2 -PLLA-L 2 -Z 2 (II) (0.5 molar equivalents) X 3 -PLLA (VII) (0.5 molar equivalents)
[0140] In this example, components (I), (II) and (VII) are mixed and the number of D-lactic acid units in component (I) is equal or approximately equal to the sum of the L-lactic acid units present in components (II) and (VII). Thus, by varying the amount of component (VII) added with the reduction of component (II), the Z-lactic acid units present in the stereocomplex can be adjusted. 1 and Z 2 It is possible to vary the relative amounts of D- and L-lactic acid units and still balance the total number of D- and L-lactic acid units to produce a stereocomplex (i.e., the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9).
[0141] In one embodiment, the PDLA or PLLA present in component (VII) has a molecular weight of about 700 Da to about 5,000 Da, or about 750 Da to 4000 Da, or about 1,000 Da to about 3,000 Da. Further, in this embodiment, the PDLA and PLLA have a molecular weight of about 700 Da, 750 Da, 800 Da, 900 Da, 1,000 Da, 1,250 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or 5,000 Da, any value can be the lower and upper end of the range (e.g., 1,000 Da to 3,000 Da). In another embodiment, the PDLA or PLLA present in component (VII) has about the same molecular weight as the PDLA and PLLA present in components (I) and (II).
[0142] In another embodiment, the number of D-lactic acid units present in PDLA or L-lactic acid units present in PLLA in component (VII) is 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100, any value being the lower and upper endpoints of a range (e.g., 10 to 60).In another embodiment, the PDLA or PLLA present in component (VII) has the same number of D-lactic acid units and L-lactic acid units as the number of D-lactic acid units and L-lactic acid units of the PDLA and PLLA present in components (I) and (II).
[0143] In one embodiment, X in component (VII) 3 is a polyalkylene glycol having a molecular weight of about 1,000 Da to about 5,000 Da, or 1,500 Da to 4,500 Da, or 2,000 Da to 4,000 Da, or having a molecular weight of about 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or about 5,000 Da, either of which values can be the lower and upper endpoints of a range (e.g., 2,000 Da to 4,000 Da).
[0144] In another embodiment, X in component (VII) 3 is a monomethoxypolyethylene glycol having a molecular weight of about 1,000 to about 5,000 Da, or 1,500 Da to 4,500 Da, or 2,000 Da to 4,000 Da, or having a molecular weight of about 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or about 5,000 Da, either of which may be the lower and upper end points of a range (e.g., 2,000 Da to 4,000 Da). In one embodiment, X in components (I), (II) and (VII) of the stereocomplex disclosed herein is 1 , X 2 and X 3 are each monomethoxypolyethylene glycols having the same molecular weight. b. Targeting group
[0145] In one embodiment, the stereocomplexes disclosed herein also include component (VIII): TA-X 4 -Y 4 (VIII) (In the formula, X 4 is a hydrophilic group as previously discussed, and Y 4 is PDLA or PLLA, and TA is a targeting agent or targeting group. In a further embodiment, the stereocomplex comprises two or more components (VIII) with different targeting groups. The targeting group TA is a hydrophilic group X 4 is covalently bonded to
[0146] In one embodiment, X 4 may be a polyalkylene glycol having a molecular weight of about 1,000 Da to about 5,000 Da. 4 The molecular weights of X in components (I) and (II) are respectively 1 and X 2 The molecular weight is greater than that of
[0147] In one embodiment, X in component (VIII) 4 is a polyalkylene glycol having a molecular weight of about 1,000 Da to about 5,000 Da, or 1,500 Da to 4,500 Da, or 2,000 Da to 4,000 Da, or having a molecular weight of about 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or about 5,000 Da, either of which values can be the lower and upper endpoints of a range (e.g., 2,000 Da to 4,000 Da).
[0148] In another embodiment, X in component (VIII) 4is a polyethylene glycol having a molecular weight of about 1,000 to about 5,000 Da, or about 1,000 Da to about 5,000 Da, or 1,500 Da to 4,500 Da, or 2,000 Da to 4,000 Da, or has a molecular weight of about 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or about 5,000 Da, either of which values can be the lower and upper endpoints of a range (e.g., 2,000 Da to 4,000 Da).
[0149] In one embodiment, the PDLA or PLLA present in component (VIII) has a molecular weight of about 700 Da to about 5,000 Da, or about 750 Da to 4000 Da, or about 1,000 Da to about 3,000 Da. Further, in this embodiment, the PDLA and PLLA have a molecular weight of about 700 Da, 750 Da, 800 Da, 900 Da, 1,000 Da, 1,250 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or 5,000 Da, any value can be the lower and upper end of the range (e.g., 1,000 Da to 3,000 Da). In another embodiment, the PDLA or PLLA present in component (VIII) has about the same molecular weight as the PDLA or PLLA present in components (I) and (II).
[0150] In another embodiment, the number of D-lactic acid units present in PDLA or L-lactic acid units present in PLLA in component (VIII) is 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100, any value being the lower and upper endpoints of a range (e.g., 10 to 60).In another embodiment, the PDLA or PLLA present in component (VII) has the same number of D-lactic acid units and L-lactic acid units as the number of D-lactic acid units and L-lactic acid units of the PDLA and PLLA present in components (I) and (II).
[0151] The use of targeting groups in the stereocomplexed compounds (VIII) described herein can better localize anticancer drugs to specific sites in the body or in specific tissue types. Moreover, in these embodiments, the targeting groups improve the specificity of the stereocomplexes to cancer cells. In further embodiments, such targeting reduces the systemic side effects of anticancer drugs. In one embodiment, the targeting group can be an antibody, an antibody fragment, an aptamer, a peptide, an oligosaccharide or other carbohydrate, a lectin or a similar molecule. As a targeting group, a structure complementary to a cell surface antigen or receptor can be used. In one embodiment, the targeting group is an antibody, an antibody fragment, a sugar, an epitope-binding peptide or an aptamer. In further embodiments, the targeting group can be a monosaccharide, a disaccharide, an oligosaccharide or a methacryloylated sugar unit; an antibody, such as IgG (rat immunoglobulin) or an antibody fragment; a protein, such as transferrin or melanocyte stimulating hormone (MSH); or a peptide. In another embodiment, the targeting group can be galactosamine, galactose, glucose, glucosamine, mannosamine, fucosylamine, lactose, folic acid derivatives, hormones (e.g., MSH, secretin), opiates, monoclonal or polyclonal antibodies. In one embodiment, the targeting group can be a Fab' derived from the OV-TL16 antibody specific for CD47 (expressed on the majority of ovarian cancer cells) or an antibody directed against prostate-specific membrane antigen (PSMA).
[0152] In one embodiment, the targeting group can be a peptide, such as arginylglycylaspartic acid (RGD), which is a specific sequence recognized by integrins. As used herein, integrins are proteins that function to attach the cytoskeleton to the extracellular matrix (ECM) and sense whether this adhesion occurs. Furthermore, in this embodiment, integrins are involved in cell adhesion to ECM and its prevention in apoptosis, tissue regeneration, and other processes related to the proliferation of cancer cells. In yet another embodiment, integrins are overexpressed on tumor cells and tumor vasculature. In one embodiment, the RGD targeting group used herein helps to deliver higher concentrations of the stereocomplexes disclosed herein to tumor tissues while minimizing interactions with nearby healthy cells. In further embodiments, the RGD targeting group can be linear or cyclic (i.e., cRGD).
[0153] In another embodiment, the targeting group can be folic acid or folate.Furthermore, in this embodiment, folate has high affinity to folate receptor, which captures the ligand and concentrates folate in the cytosol using endocytosis mechanism.In one embodiment, folate receptor is overexpressed on the surface of malignant cancer cells and activated macrophages.In some embodiments, activated macrophages are found in inflammatory tissues and tissues with a wide range of symptoms of disease.Furthermore, in this embodiment, using folate ligand as targeting group can help localize the stereocomplex disclosed herein in the vicinity of tumor or other areas of diseased tissue.
[0154] In one embodiment, component VIII has the structure [ka] (In the formula, n 3 is 45 to 90, m 3 is 15 to 60, C aThe stereochemistry in is R or S. has.
[0155] In one embodiment, the targeting group (TA) in structure XV can be a sugar that is unsubstituted or substituted. Examples of sugars useful herein include, but are not limited to, glucose, ribose, galactose, mannose, fructose, fuculose, glucosamine, or fucoidan. In one embodiment, the targeting group in structure XV is glucose or a substituted glucose. In another embodiment, the targeting group in structure XV is glucose substituted with one or more alkyl groups as defined herein, and one or more hydroxyl protons of glucose can be substituted with alkyl groups. In another embodiment, the targeting group in structure XV is glucose substituted with one or more methyl, ethyl, or propyl groups. In another embodiment, the targeting group in structure XV is glucose substituted with one methyl group. In another embodiment, the targeting group in structure XV is glucose with the C1 hydroxyl proton substituted with a methyl group. In one embodiment, the targeting group in structure XV is methyl-α-glucose or methyl-β-glucose. In another embodiment, the targeting group in structure XV is methyl-α-glucose, where the methylated glucose moiety is covalently attached to the carbonyl group in structure XV at the C6 hydroxyl position, as depicted in FIG.
[0156] Without wishing to be bound by theory, according to the Warburg effect, cancer cells require more glucose for faster growth. In some embodiments, glucose transport is supported by GLUT family and SGLT family. SGLT transporters are found in both early and late stages of tumor growth, while upregulated GLUT transporters are usually found in late stages of tumor development. Furthermore, in this embodiment, the use of sugars, such as glucose or substituted glucose, as targeting groups can increase the uptake and infiltration of the stereocomplexes described herein near or inside tumors, which ultimately leads to improved therapeutic efficacy.
[0157] In one embodiment, the targeting group is a ligand for a cell-surface receptor on a cell, such as a cancer cell or an endothelial cell that is part of the vasculature of, for example, a solid tumor. In one embodiment, the biorecognition of the targeting group on the cell surface leads to increased uptake of the stereocomplex by receptor-mediated endocytosis, pinocytosis or another selective mechanism. In a further embodiment, this increased uptake leads to improved therapeutic efficacy.
[0158] In another embodiment, intracellular targeting to specific organelles can be achieved by using specific targeting agents.In a further embodiment, mitochondria can be targeted using positively charged triphenylphosphonium ions linked to the stereocomplexes disclosed herein previously described.In a related embodiment, nuclear targeting can be achieved by using steroid hormones as targeting groups.An example of component (VIII) is presented in Figure 3.
[0159] The inclusion of component (VIII) allows for modification of the molar ratio of anticancer drugs present in the stereocomplex while maintaining the optimal ratio of D- and L-lactic acid units for the formation of the stereocomplex. As an example, the following scheme shows the synthesis of Z-lactic acid using component (VIII): 1 :Z 2is presented to demonstrate how to produce a stereocomplex with a 2:1 ratio, where the total number of D-lactic acid units is equal to the total number of L-lactic acid units. X 1 -PDLA-L 1 -Z 1 (I) (1 molar equivalent) X 2 -PLLA-L 2 -Z 2 (II) (0.5 molar equivalents) TA-X 4 -PLLA (VIII) (0.5 molar equivalents)
[0160] In this example, components (I), (II) and (VIII) are mixed, and the number of D-lactic acid units in component (I) is equal to or approximately equal to the sum of the L-lactic acid units present in components (II) and (VIII). Thus, by varying the amount of component (VIII) added with the decrease in component (II), the Z-lactic acid units present in the stereocomplex can be adjusted. 1 and Z 2 It is possible to vary the relative amounts of D- and L-lactic acid units and still balance the total number of D- and L-lactic acid units to produce a stereocomplex (i.e., the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9).
[0161] In another embodiment, component (VII) can be added to components (I), (II) and (VIII) to produce a stereocomplex. As an example, the following scheme shows the Z 1 :Z 2 is presented to demonstrate how to produce a stereocomplex with a 2:1 ratio, where the total number of D-lactic acid units is equal to the total number of L-lactic acid units. X 1 -PDLA-L 1 -Z 1 (I) (1 molar equivalent) X 2 -PLLA-L2 -Z 2 (II) (0.5 molar equivalents) X 3 -PLLA (VII) (0.25 molar equivalents) TA-X 4 -PLLA (VIII) (0.25 molar equivalents) c. Additional anticancer drugs
[0162] In another aspect, the stereocomplex disclosed herein has formula (IX): X 5 -Y 5 -L 5 -Z 5 (IX) (In the formula, X 5 is a hydrophilic group as previously described, and Y 5 is PDLA or PLLA, L 5 is a cleavable linker, and each Z 5 is an anticancer agent as described herein, Z 5 is Z 1 and Z 2 is different from The composition may include one or more components having the formula:
[0163] In one embodiment, X 5 In another embodiment, X in component (IX) may be a polyalkylene glycol having a molecular weight of about 1,000 Da to about 5,000 Da. 5 is a polyalkylene glycol having a molecular weight of about 1,000 Da to about 5,000 Da, or 1,500 Da to 4,500 Da, or 2,000 Da to 4,000 Da, or having a molecular weight of about 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or about 5,000 Da, either of which values can be the lower and upper endpoints of a range (e.g., 2,000 Da to 4,000 Da).
[0164] In another embodiment, X in component (IX) 5is a polyethylene glycol having a molecular weight of about 1,000 to about 5,000 Da, or 1,500 Da to 4,500 Da, or 2,000 Da to 4,000 Da, or has a molecular weight of about 1,000 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or about 5,000 Da, either of which values can be the lower and upper endpoints of a range (e.g., 2,000 Da to 4,000 Da).
[0165] In one embodiment, the PDLA or PLLA present in component (IX) has a molecular weight of about 700 Da to about 5,000 Da, or about 750 Da to 4000 Da, or about 1,000 Da to about 3,000 Da. Further, in this embodiment, the PDLA and PLLA have a molecular weight of about 700 Da, 750 Da, 800 Da, 900 Da, 1,000 Da, 1,250 Da, 1,500 Da, 2,000 Da, 2,500 Da, 3,000 Da, 3,500 Da, 4,000 Da, 4,500 Da, or 5,000 Da, any value can be the lower and upper end of the range (e.g., 1,000 Da to 3,000 Da). In another embodiment, the PDLA or PLLA present in component (IX) has about the same molecular weight as the PDLA and PLLA present in components (I) and (II).
[0166] In another embodiment, the number of D-lactic acid units present in PDLA or L-lactic acid units present in PLLA in component (IX) is 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100, any value being the lower and upper endpoints of a range (e.g., 10 to 60).In another embodiment, the PDLA or PLLA present in component (IX) has the same number of D-lactic acid units and L-lactic acid units as the number of D-lactic acid units and L-lactic acid units of the PDLA and PLLA present in components (I) and (II).
[0167] In one embodiment, L 5includes a cleavable group as described herein, including, but not limited to, a disulfide group, an ester group, a hydrazone group, an acetal group, an imine group, a β-thiopropionate group, or an amide group. 5 may contain one or more of these groups. 5 can also contain additional functional groups so that the cleavable linker can be covalently attached to the PDLA or PLLA.
[0168] In some embodiments, by thus incorporating one or more than one moiety of formula (VIII) into the stereocomplex, additional anti-cancer drugs can be administered to the subject. In one embodiment, three, four or more than four anti-cancer drugs can be incorporated into the stereocomplexes described herein.
[0169] The inclusion of component (IX) allows for modification of the molar ratio of anticancer drugs present in the stereocomplex while maintaining the optimal ratio of D- and L-lactic acid units for the formation of the stereocomplex. As an example, the following scheme shows the synthesis of Z-lactic acid using component (IX): 1 :Z 2 :Z 5 is presented to demonstrate how to produce a stereocomplex with a 2:1:1 ratio, where the total number of D-lactic acid units is equal to the total number of L-lactic acid units. X 1 -PDLA-L 1 -Z 1 (I) (1 molar equivalent) X 2 -PLLA-L 2 -Z 2 (II) (0.5 molar equivalents) X 5 -PLLA-L 5 -Z 5 (IX) (0.5 molar equivalents)
[0170] In this example, components (I), (II) and (IX) are mixed, and the number of D-lactic acid units in component (I) is equal or approximately equal to the sum of the L-lactic acid units present in components (II) and (VIII). Thus, by varying the amount of component (IX) added with the decrease in component (II), the Z-lactic acid units present in the stereocomplex can be adjusted. 1 , Z 2 and Z 5 It is possible to vary the relative amounts of D- and L-lactic acid units and still balance the total number of D- and L-lactic acid units to produce a stereocomplex (i.e., the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9).
[0171] In other embodiments, components (VII) and / or (VIII) can be added to components (I), (II) and (IX) to form a stereocomplex. D. Adjuvant
[0172] In one embodiment, one or more adjuvants can be incorporated into the stereocomplexes described herein. For example, an adjuvant can be combined with components I and II described herein to produce a stereocomplex that includes the adjuvant.
[0173] In one aspect, the adjuvant targets stromal cells. As used herein, "stromal cells" are connective tissue cells in any organ that together form the stroma. In a further aspect, the interaction of stromal cells and cancer cells plays a role in cancer progression. In yet another aspect, stromal cells can release growth factors that promote cell division or provide extracellular matrix that supports tumor cells. In a further aspect, a stroma-rupturing agent can be used in the compositions disclosed herein. In one aspect, the stroma-rupturing agent can be, for example, an angiotensin receptor blocker, such as losartan, azilsartan, candesartan, eprosartan, irbesartan, olmesartan, telmisartan, valsartan, or a combination thereof. In another embodiment, the interstitial bursting agent can be a flavonoid such as, for example, luteolin, quercetin, genistein, catechin, cyaniding, naringenin, delphinidin, malvidin, petunidin, peonidin, pelargonidin, gallocatechin, catechin-3-gallate, epicatechin, epigallocatechin, daidzein, glycetein, equol, kaempferol, myricetin, eriodictyol, hesperitin, taxifolin, or combinations thereof.
[0174] In another embodiment, the adjuvant can target fibrosis and / or cancer-promoted fibrosis. In a further embodiment, fibrosis is a component of the tumor microenvironment and can significantly affect cancer behavior. In a further embodiment, fibrosis is characterized by the infiltration and proliferation of multipotent stromal cells (i.e., mesenchymal cells) in the interstitial space. In a further embodiment, antifibrotic agents can be used in the compositions disclosed herein. In one embodiment, the antifibrotic agent can be, for example, a pyridine, such as pirfenidone, mimosine, ciclopirox, diodon, bemeglide, deferiprone, or a combination thereof. In another embodiment, the antifibrotic agent can be N-acetylcysteine, etanercept, bosentan, sildenafil, nintedanib, colchicine, or a combination thereof.
[0175] In another embodiment, the adjuvant may be an aromatase inhibitor (anastrozole, letrozole, exemestane), an estrogen blocker (tamoxifen, toremifene, fulvestrant, fulvestrant), an ovarian function blocker (goserelin, leuprolide), a gonadotropin releasing hormone agonist (buserelin, histrelin, leuprorelin, triptorelin, nafarelin), an estrogen modulator (toremifene citrate), a progestin therapeutic (megestrol acetate), an LHRH agonist (pharmagon), an androgen reducing agent (abiraterone, ketoconazole), an antiandrogen drug (flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, darolutamide), etc. In some embodiments, these therapies may be used as adjuvants in the methods disclosed herein.
[0176] In yet another embodiment, immunotherapies can be used as adjuvants in conjunction with the methods disclosed herein. In one embodiment, these can include immunosuppressants including corticosteroids (hydrocortisone), methotrexate, and interferons (e.g., interferon alpha-2A, alpha-2b, alpha-n3, beta-1a, beta-1b, gamma-1b, etc.). e. Exemplary Constituents and Stereocomplexes
[0177] In one embodiment, disclosed herein is a stereocomplex, wherein component (I) has the following features: X 1 is a monomethoxypolyethylene glycol having a molecular weight of about 2,000 Da to about 4,000 Da, and the number of L-lactic acid units or D-lactic acid units is about 15 to about 60, 1 contains a disulfide group, Z 1 is mertansine (DM1). Additionally, in this embodiment, the components can be abbreviated as Lss-DM1 and / or Dss-DM1, which further specify the polymer stereochemistry, the linker group and the anticancer drug.
[0178] In another embodiment, component (I) has the structure (III): [ka] (In the formula, n 1 is 45 to 90, m 1 is 15 to 60, o is 1 to 4; C a The stereochemistry in is R or S. Disclosed herein is a stereocomplex having the following structure:
[0179] In a further embodiment, o in formula (III) is 2.
[0180] In another aspect, disclosed herein is a stereocomplex, wherein component (II) has the following features: X 2 is a monomethoxypolyethylene glycol having a molecular weight of about 2,000 Da to about 4,000 Da, and the number of L-lactic acid units or D-lactic acid units is about 15 to about 60, 2 contains an ester, hydrazone or disulfide group, Z 2 is docetaxel. In any of these embodiments, docetaxel may be abbreviated as DTX (e.g., Lss-DTX refers to a stereocomplex component having PLLA, a disulfide linkage, and docetaxel).
[0181] In another embodiment, component (II) has the structure (IV): [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, p is 0 to 7; C a The stereochemistry in is R or S. Disclosed herein is a stereocomplex having the following structure:
[0182] In one embodiment, p in formula (IV) is 2.
[0183] In yet another embodiment, component (II) has the structure (V): [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; q is 1 to 7; C aThe stereochemistry in is R or S. Disclosed herein is a stereocomplex having the following structure:
[0184] In a further embodiment, each p is 2 and q is 3.
[0185] In yet another embodiment, component (II) has the structure (VI): [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; C a The stereochemistry in is R or S. Disclosed herein is a stereocomplex having the following structure:
[0186] In another embodiment, in structure (VI), each p is 2. f. Pharmaceutical Compositions
[0187] The stereocomplexes described herein can be combined with at least one pharma- ceutically acceptable carrier to produce a pharmaceutical composition.The pharmaceutical composition can be prepared using techniques known in the art.In one embodiment, the pharmaceutical composition is prepared by mixing the stereocomplexes with a pharma- ceutically acceptable carrier.
[0188] Pharmaceutically acceptable carriers are known to those of skill in the art. These most typically are standard carriers including solutions such as sterile water, saline, and buffered solutions at physiological pH for administration to humans and / or other mammals.
[0189] The molecules intended for pharmaceutical delivery may be formulated into pharmaceutical compositions. The pharmaceutical compositions may contain carriers, thickeners, diluents, buffers, preservatives, surface active agents, etc., in addition to the stereocomplexes described herein. The pharmaceutical compositions may also contain one or more additional active ingredients, such as antimicrobial agents, anti-inflammatory agents, anesthetic agents, etc.
[0190] The pharmaceutical compositions can be administered in a number of ways, depending on whether local or systemic treatment is desired and on the area to be treated. Administration can be parenteral, oral, subcutaneous, intralesional, intraperitoneal, intravenous or intramuscular.
[0191] Preparations for administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous carriers include alcoholic / aqueous solutions, emulsions, or suspensions including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils, if necessary for concomitant use of the disclosed compositions and methods. Intravenous vehicles include fluid and nutrient supplements, electrolyte supplements (such as those based on Ringer's dextrose), etc., if necessary for concomitant use of the disclosed compositions and methods. Preservatives and other additives may also be present, such as, for example, antibacterial agents, antioxidants, chelating agents, inert gases, etc.
[0192] In one aspect, provided herein is a pharmaceutical composition comprising a stereocomplex described herein and a pharma- ceutically acceptable carrier or excipient. Preparation and characterization of stereocomplexes
[0193] In any of the above embodiments, the solution of PLLA- and PDLA-conjugated polymers dissolved in a compatible organic solvent and the anticancer drug and / or imaging agent can be mixed together under stirring, and then the solvent is replaced with a buffer to prepare the stereocomplexes described herein. As with the precursor components, in some embodiments, the particle size of the stereocomplexes can be characterized using dynamic light scattering. In further embodiments, the melting temperature of the crystalline anticancer drug, the prepared prodrug, and the stereocomplexes can be characterized using techniques such as, for example, differential scanning calorimetry. Non-limiting methods for generating stereocomplexes are provided in the examples.
[0194] In one embodiment, the stereocomplexes herein are nanoparticles. In further embodiments, the stereocomplexes have an average diameter of 50-500 nm, or 100-400 nm, or 100-200 nm. In yet other embodiments, the diameter of the nanoparticles can be measured using dynamic light scattering (DLS), transmission electron microscopy (TEM), scanning electron microscopy (SEM), atomic force microscopy (AFM), photon correlation spectroscopy (PCS), X-ray diffraction (XRD) or other methods. Stereo Complex Applications
[0195] The stereocomplexes described herein are effective for delivering one, preferably two or more anti-cancer drugs to a subject using a single delivery device. The selection of cleavable linkers can be varied for each component in the stereocomplex to deliver each anti-cancer drug at a specific rate (e.g., immediate release, delayed release, controlled release). Depending on the type of cancer being treated, the selection of anti-cancer drug and cleavable linker can be fine-tuned to maximize the efficiency of the stereocomplex to treat cancer. As demonstrated below, stereocomplexes allow for the safe delivery of two anti-cancer drugs while minimizing unwanted side effects associated with co-administration of drugs. Furthermore, stereocomplexes allow for the delivery of anti-cancer drugs such that the drugs affect each other synergistically.
[0196] In one aspect, when the stereocomplex is a nanoparticle, tumor targeting is improved by using the "enhanced permeability and retention (EPR) effect". As used herein, "enhanced permeability and retention (EPR) effect" refers to the tendency of nanoparticles to accumulate more in tumor tissue than in healthy tissue. In one aspect, the stereocomplexes disclosed herein, due to their average particle size, tend to accumulate in or near cancer cells in the absence or in addition to any specific cell targeting.
[0197] In another aspect, the stereocomplexes have improved resistance to hydrolytic degradation. Without wishing to be bound by theory, due to the hydrophilic nature of the stereocomplexes, the hydrophilic linker can form a thick dynamic hydration shell around the nanoparticles, which can prevent the absorption of serum proteins to the surface of the nanoparticles. Furthermore, the hydrophilic linker of the stereocomplexes can reduce opsonization and clearance by the mononuclear phagocyte system (MPS), thereby extending blood circulation time.
[0198] In another aspect, provided herein is a method for treating cancer in a subject, comprising administering to the subject a stereocomplex as disclosed herein. In a further aspect, the cancer may be pancreatic cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, nasopharyngeal cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, gastric adenocarcinoma, head cancer, neck cancer, brain cancer, oral cancer, pharyngeal cancer, thyroid cancer, esophageal cancer, gallbladder cancer, liver cancer, rectal cancer, kidney cancer, uterine cancer, bladder cancer, testicular cancer, lymphoma, myeloma, melanoma, leukemia, or non-specific solid tumor.
[0199] In an alternative embodiment, provided herein is a method for reducing the size of a tumor in a subject, comprising administering to the subject a stereocomplex as disclosed herein. In one embodiment, the stereocomplex can reduce the weight or volume of an existing tumor by 10% to 100% when compared to a control (i.e., no treatment with the stereocomplex). In another embodiment, the stereocomplex can reduce the weight or volume of an existing tumor by 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%, any value can be the lower and upper endpoints of a range (e.g., 30% to 70%, 50% to 90%, etc.). In one embodiment, the stereocomplex can eliminate the tumor such that the tumor is no longer present and does not return (i.e., remission). In another embodiment, the stereocomplexes are capable of preventing (ie, inhibiting) the growth of existing tumors.
[0200] In one embodiment, the stereocomplex disclosed herein can be administered to a subject in need of cancer treatment by intravenous injection, either alone or in combination with a pharma- ceutically acceptable carrier or excipient to form a pharmaceutical composition.In one embodiment, the stereocomplex can be administered to a subject at least once a week, at least twice a week, or at least three times a week.In other embodiments, the stereocomplex can be administered every 2 weeks, 3 weeks, 4 weeks, 6 weeks, or 8 weeks.
[0201] In another embodiment, different populations of stereocomplexes can be administered to a subject. For example, a specific ratio of anticancer drugs (e.g., Z:1) can be administered to a subject. 1 :Z 2 A first population of stereocomplexes composed of components (I) and (II) having a Z ratio of 1:1 can be prepared and administered, followed by administration of a second population (e.g., a 1:1 Z ratio of 1:1). 1 :Z 2 Alternatively, the second population may be subsequently administered a different anticancer drug combination (Z 1 :Z 5 or Z 2 :Z 5 ) may be included.
[0202] In one embodiment, the anticancer agent Z 1 and anti-cancer drug Z 2 is 10:1 to 1:10, or about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10, any value which can be the lower and upper endpoints of a range (e.g., 5:1 to 1:5).
[0203] In a further embodiment, Z in component (I) 1 is mertansine, and Z in component (I) 2is docetaxel. In another embodiment, the stereocomplex has a molar ratio of mertansine to docetaxel of about 4:1 to about 1:10, or a ratio of 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10, any value of which can be the lower and upper endpoints of the range (e.g., 5:1 to 1:5). In one embodiment, the ratio of mertansine to docetaxel is about 1:6 to about 1:10.
[0204] In another embodiment, when the stereocomplex contains mertansine and docetaxel as anticancer drugs, the molar ratio of each drug may vary depending on the cancer to be treated.Below is a table presenting the molar ratios of the components described herein to generate stereocomplexes for treating various types of cancer (cell lines are in brackets, components (III), (IV) and (V) defined above). [Table 3]
[0205] In one embodiment, the dosage of DM1 administered to a subject in a stereocomplex is about 2 mg / kg to about 5 mg / kg of body weight, or about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, or about 5 mg / kg, either of which can be the lower and upper endpoints of a range (e.g., about 2.5 mg / kg to about 4 mg / kg, about 3.5 mg / kg to about 4.5 mg / kg, etc.). In another embodiment, the dosage of docetaxel administered to a subject in a stereocomplex is about 12 mg / kg to about 50 mg / kg of body weight, or about 12, about 15, about 20, about 25, about 30, about 35, about 40, about 45, or about 50 mg / kg, any of which can be the lower and upper endpoints of a range (e.g., about 15 mg / kg to about 40 mg / kg, about 25 to about 35 mg / kg, etc.).
[0206] In one embodiment, the single unit dose of DM1 administered to a subject in a stereocomplex is about 0.5 mg / m2 ~about 15mg / m 2 and the unit is mg / m 2 is the body surface area calculated for height and weight. In another embodiment, a single unit dose of DM1 administered to a subject in a stereocomplex is about 0.5 mg / m 2 , 1 mg / m 2 , 1.5 mg / m 2 , 2 mg / m 2 , 2.5 mg / m 2 , 3 mg / m 2 , 3.5 mg / m 2 , 4 mg / m 2 , 4.5 mg / m 2 , 5 mg / m 2 , 5.5 mg / m 2 , 6 mg / m 2 , 6.5 mg / m 2 , 7 mg / m 2 , 7.5 mg / m 2 , 8 mg / m 2 , 8.5 mg / m 2 , 9 mg / m 2 , 9.5 mg / m 2 , 10 mg / m 2 , 10.5 mg / m 2 , 11 mg / m 2 , 11.5 mg / m 2 , 12 mg / m 2 , 12.5 mg / m 2 , 13 mg / m 2 , 13.5 mg / m 2 , 14 mg / m 2 , 14.5 mg / m 2 , 15 mg / m 2 and either value can be the lower and upper endpoints of a range (e.g., about 1 mg / m 2 ~about 6mg / m 2 , about 3mg / m 2 ~about 5mg / m 2 etc.).
[0207] In one embodiment, the single unit dose of docetaxel administered to a subject in a stereocomplex is about 3 mg / m 2 ~about 135mg / m 2 and the unit is mg / m 2is the body surface area calculated for height and weight. In another embodiment, the single unit dose of docetaxel administered to a subject in a stereocomplex is about 3 mg / m 2 , 5 mg / m 2 , 10 mg / m 2 , 15 mg / m 2 , 20 mg / m 2 , 25 mg / m 2 , 30 mg / m 2 , 35 mg / m 2 , 40 mg / m 2 , 45 mg / m 2 , 50 mg / m 2 , 55 mg / m 2 , 60 mg / m 2 , 65 mg / m 2 , 70 mg / m 2 , 75 mg / m 2 , 80 mg / m 2 , 85 mg / m 2 , 90 mg / m 2 , 95 mg / m 2 , 100 mg / m 2 , 105 mg / m 2 , 110 mg / m 2 , 115 mg / m 2 , 120 mg / m 2 , 125 mg / m 2 , 130 mg / m 2 , 135 mg / m 2 and either value can be the lower and upper endpoints of a range (e.g., about 5 mg / m 2 ~about 70mg / m 2 , about 20mg / m 2 ~about 60mg / m 2 etc.).
[0208] In one embodiment, chemotherapy with the stereocomplexes disclosed herein can be used in combination with one or more other treatment strategies, including, but not limited to, surgical removal of all or part of the tumor or diseased organ or tissue, radiation therapy, high intensity focused ultrasound, magnetic hyperthermia, photothermia, immunotherapy, or a combination thereof. Aspects
[0209] The following list of exemplary embodiments is supported by and supported by the disclosure provided herein.
[0210] Aspect 1: Components X 1 -Y 1 -L 1 -Z 1 (I) X 2 -Y 2 -L 2 -Z 2 (II) (In the formula, each X 1 and X 2 is a hydrophilic group, Each Y 1 and Y 2 is PDLA or PLLA, Each L 1 and L 2 is a cleavable linker, Z 1 is an anticancer drug, Z 2 is an anti-cancer agent or imaging agent, and Z 2 If is an anticancer drug, Z 1 and Z 2 are different anticancer drugs, (1) Y 1 If is PDLA, then Y 2 is PLLA, and Y 1 If is PLLA, Y 2 is PDLA, and (2) the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9. Stereo Complex, including.
[0211] Aspect 2: X 1 and X 2 are different hydrophilic groups.
[0212] Aspect 3: X 1 and X2 are the same hydrophilic group.
[0213] Aspect 4: X 1 and X 2 and each is a polyalkylene glycol.
[0214] Aspect 5: X 1 and X 2 and each of the above is a polyalkylene glycol having a molecular weight of 1,000 Da to 5,000 Da.
[0215] Aspect 6: X 1 and X 2 and each of the above is a polyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da.
[0216] Aspect 7: X 1 and X 2 and each of the above is monomethoxypolyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da.
[0217] Embodiment 8: A stereocomplex according to any one of embodiments 1 to 7, wherein PDLA and PLLA have a molecular weight of 700 Da to 5,000 Da.
[0218] Aspect 9: L 1 and L 2 A stereocomplex according to any one of the preceding embodiments, wherein:
[0219] Aspect 10: L 1 and L 2 A stereocomplex according to any one of the preceding embodiments, wherein:
[0220] Aspect 11: L 1 and L 2A stereocomplex according to any one of the preceding embodiments, wherein independently contains a disulfide group, an ester group, a hydrazone group, an acetal group, an imine group, a β-thiopropionate group, or an amide group.
[0221] Aspect 12: Z 1 and Z 2 is independently paclitaxel, doxorubicin, gemcitabine, cisplatin, methotrexate, 5-fluorouracil, betulinic acid, amphotericin B, diazepam, nystatin, propofol, testosterone, estrogen, prednisolone, prednisone, 2,3 mercaptopropanol, progesterone, docetaxel, maytansinoid, PD-1 inhibitor, PD-L1 inhibitor, protein kinase inhibitor, P-glycoprotein inhibitor, autophagy inhibitor, PARP inhibitor, aromatase inhibitor, monoclonal antibody, photosensitizer, radiosensitizer, interleukin, antiandrogen, or any combination thereof.
[0222] Embodiment 13: A stereocomplex according to embodiment 12, wherein the maytansinoid is ansamitocin, mertansine (DM1) or ravtansine.
[0223] Aspect 14: Z 1 and Z 2 A stereocomplex according to any one of aspects 1 to 13, wherein the molar ratio of
[0224] Aspect 15: Z 1 is mertansine, and Z 2 15. The stereocomplex according to any one of the preceding embodiments, wherein is docetaxel.
[0225] Aspect 16: For component I, X 1 is a monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, the number of L-lactic acid units or D-lactic acid units is 15 to 60, and L 1contains a disulfide group, Z 1 16. The stereocomplex according to any one of the preceding aspects, wherein is mertansine (DM1).
[0226] Aspect 17: Component I has the following structure: [ka] (In the formula, n 1 is 45 to 90, m 1 is 15 to 60, o is 1 to 4; C a The stereochemistry in is R or S. 17. The stereocomplex according to embodiment 16, having the following structure:
[0227] Embodiment 18: A stereocomplex according to embodiment 17, wherein o is 2.
[0228] Aspect 19: Regarding component II, X 2 is a monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, the number of L-lactic acid units or D-lactic acid units is 15 to 60, and L 2 contains an ester, hydrazone, or disulfide group; Z 2 A stereocomplex according to any one of embodiments 16 to 18, wherein is docetaxel.
[0229] Aspect 20: A stereocomplex according to aspect 19, wherein the molar ratio of mertansine to docetaxel is from 4:1 to 1:10.
[0230] Aspect 21: Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, p is 0 to 7; C a The stereochemistry in is R or S. 20. The stereocomplex according to embodiment 19, having the following structure:
[0231] Embodiment 22: A stereocomplex according to embodiment 21, wherein p is 2.
[0232] Aspect 23: Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; q is 1 to 7; C a The stereochemistry in is R or S. 20. The stereocomplex according to embodiment 19, having the following structure:
[0233] Embodiment 24: A stereocomplex according to embodiment 23, wherein each p is 2 and q is 3.
[0234] Aspect 25: Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; C a The stereochemistry in is R or S. 20. The stereocomplex according to embodiment 19, having the following structure:
[0235] Embodiment 26: A stereocomplex according to embodiment 25, wherein each p is 2.
[0236] Aspect 27: Component VII X 3 -Y 3 (VII) (In the formula, X 3 is a hydrophilic group, Y 3 is PDLA or PLLA) 27. The stereocomplex according to any one of the preceding embodiments, further comprising:
[0237] Aspect 28: X 3 is a polyalkylene glycol having a molecular weight of 1,000 Da to 5,000 Da.
[0238] Aspect 29: X 3 is a polyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da.
[0239] Aspect 30: X 3 is monomethoxypolyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da.
[0240] Aspect 31: X 3 is monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, and the number of L-lactic acid units or D-lactic acid units present in PDLA or PLLA is 15 to 60.
[0241] Aspect 32: Component VIII TA-X 4 -Y 4 (VIII) (In the formula, X 4 is a hydrophilic group, Y 4 is PDLA or PLLA, TA is a targeting group 32. The stereocomplex according to any one of the preceding embodiments, further comprising:
[0242] Aspect 33: X 4 is a polyalkylene glycol having a molecular weight of 1,000 Da to 5,000 Da, and X 4 The molecular weight of X 1 and X 2 33. The stereocomplex according to embodiment 32, having a molecular weight of greater than
[0243] Aspect 34: X 4 is a polyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da, and X 4 The molecular weight of X 1 and X 2 33. The stereocomplex according to embodiment 32, having a molecular weight of greater than
[0244] Aspect 35:X 4 is a polyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, and the number of L-lactic acid units or D-lactic acid units present in PDLA or PLLA is 15 to 60.
[0245] Embodiment 36: A stereocomplex according to embodiment 32, wherein TA is a ligand.
[0246] Aspect 37: Component VIII has the structure: [ka] (In the formula, n 3 is 45 to 90, m 3 is 15 to 60, C a The stereochemistry in is R or S. 33. The stereocomplex according to embodiment 32, having the following structure:
[0247] Embodiment 38 A stereocomplex according to embodiment 32, wherein TA is an unsubstituted or substituted sugar.
[0248] Embodiment 39: A stereocomplex according to embodiment 38, wherein the sugar is ribose, galactose, mannose, fructose, fuculose, glucosamine or fucoidan.
[0249] Embodiment 40: A stereocomplex according to embodiment 32, wherein TA is glucose or a substituted glucose.
[0250] Embodiment 41: A stereocomplex according to embodiment 40, wherein TA is an alkyl-substituted glucose.
[0251] Embodiment 42: A stereocomplex according to embodiment 40, wherein TA is methyl-α-glucose or methyl-β-glucose.
[0252] Aspect 43: Formula IX X 5 -Y 5 -L 5 -Z 5 (IX) (In the formula, X 5 is a hydrophilic group, Y 5 is PDLA or PLLA, L 5 is a cleavable linker, Z 5 is an anticancer drug, Z 5 is Z 1 and Z 2 is different from 43. The stereocomplex according to any one of the preceding embodiments, further comprising one or more components:
[0253] Aspect 44:Z 2 45. The stereocomplex according to any one of the preceding embodiments, wherein: is an imaging agent, and the imaging agent comprises a radiopharmaceutical, a radiological contrast agent, an optical imaging agent or a precursor thereof, a quantum dot, or a combination thereof.
[0254] Aspect 45: A radiopharmaceutical comprising: 11 CL-methyl-methionine, 18 F-fluorodeoxyglucose, 18 F - sodium fluoride, 18 F fluorocholine, 18 F Desmethoxyfalipride, 67 Ga-Ga 3+ , 68 Ga-dotatoc, 68 Ga-PSMA, 111 In-Diethylenetriaminepentaacetic acid, 111 In-white blood cells, 111 In-platelets, 111 In-Penetreotide, 111 In-Octreotide, 123 I-iodide, 123 Io-iodine hiprate, 123 Im-iodobenzylguanidine, 123 I-FP-CIT, 125 I-fibrinogen, 131 I-iodide, 131 Im-iodobenzylguanidine, 81 Kr m -gas, 81 Kr m -aqueous solution, 13 N-ammonia, 15 O-water, 75 Se-selenolcholesterol, 75 Se-seleno-25-homo-tauro-cholate, 120 Tl-Tl + , 133 Xe-gas, 133 Xe (in isotonic sodium chloride solution), 99 Tc m -Pertechnetate, containing macroaggregates or microspheres 99 Tc m - human albumin, 99 Tc m phosphonates and / or phosphates, 99 Tc m -diethylenetriaminepentaacetic acid, 99 Tc m -dimercaptosuccinic acid, 99 Tcm -colloid, 99 Tc m -Hepatic iminodiacetic acid, 99 Tc m whole red blood cells, 99 Tc m -Mercaptoacetyltriglycine, containing Examethazime-labeled leukocytes 99 Tc m Examethadim, 99 Tc m Sesta-methoxyisobutylisonitrile, 99 Tc m IMMU-MN3 mouse Fab'-SH anti-granulocyte monoclonal antibody fragment, 99 Tc m -Technegas, 99 Tc m Human immunoglobulin, 99 Tc m - tetrofosmin, 99 Tc m 45. The stereocomplex according to embodiment 44, comprising -ethyl cysteinate dimer, or another radiopharmaceutical.
[0255] Embodiment 46: A stereocomplex according to embodiment 44, wherein the radiological imaging agent comprises diatrizoate, metrizoate, iothalamate, ioxaglate, iopamidol, iohexol, ioxilan, iopromide, iodixanol, ioversol, another iodine imaging agent, barium sulfate, gadoterate, gadodiamide, gadobenate, gadopentetate, gadoteridol, gadofosveset, gadoversetamide, gadoxetate, gadobutrol, or another gadolinium chelator.
[0256] Embodiment 47: The stereocomplex according to embodiment 44, wherein the optical imaging agent or precursor thereof comprises methylene blue, indigo carmine, another non-specific dye, fluorescein isothiocyanate, indocyanine green, rosamine, a BODIPY (boron-dipyrromethane) derivative, a chalcone, a xanthone, an oxazole yellow, a thiazole orange, a fluorescein, a luciferin, Texas red, a squaraine, a porphyrin, a phthalocyanine, a polymethine cyanine dye comprising Cy3, Cy5, Cy5.5 or Cy7, an Alexa fluor, 5-aminolevulinic acid, a metal chelator or another optical imaging agent.
[0257] Embodiment 48: A stereocomplex according to any one of embodiments 1 to 47, further comprising an adjuvant.
[0258] Embodiment 49: A stereocomplex according to embodiment 48, wherein the adjuvant comprises an interstitial disrupting agent, an anti-fibrotic agent, an aromatase inhibitor, an immunosuppressant, an estrogen blocker, a gonadotropin releasing hormone agonist, an estrogen modulator, a progestin therapeutic agent, an LHRH agonist, an androgen reducing agent, an antiandrogen, an immunosuppressant or any combination thereof.
[0259] Embodiment 50: A stereocomplex according to embodiment 48, wherein the adjuvant comprises a stromal-rupturing agent, the stromal-rupturing agent comprising losartan, azilsartan, candesartan, eprosartan, irbesartan, olmesartan, telmisartan, valsartan, luteolin, quercetin, genistein, catechin, cyaniding, naringenin, delphinidin, malvidin, petunidin, peonidin, pelargonidin, gallocatechin, catechin-3-gallate, epicatechin, epigallocatechin, daidzein, glycitein, equol, kaempferol, myricetin, eriodictyol, hesperitin, taxifolin, or any combination thereof.
[0260] Embodiment 51: A stereocomplex according to embodiment 48, wherein the adjuvant comprises an antifibrotic agent, and the antifibrotic agent comprises pirfenidone, mimosine, ciclopirox, diodon, bemeglide, deferiprone, etanercept, bosentan, sildenafil, nintedanib, colchicine or a combination thereof.
[0261] Aspect 52: Component I has the following structure: [ka] (In the formula, n 1 is 45 to 90, m 1 is 15 to 60, o is 1 to 4; C a is R or S), Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; q is 1 to 7; C a The stereochemistry in is R or S. having The ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9. 2. A stereocomplex according to embodiment 1.
[0262] Embodiment 53: A stereocomplex according to embodiment 52, wherein o is 2, each p is 2 and q is 3.
[0263] Embodiment 54: A stereocomplex according to any one of embodiments 1 to 53, having an average diameter of 50 nm to 200 nm.
[0264] Embodiment 55: A pharmaceutical composition comprising a stereocomplex according to any one of embodiments 1 to 54, and a pharma- ceutically acceptable carrier.
[0265] Embodiment 56: A method for treating cancer in a subject, comprising administering to the subject a stereocomplex according to any one of embodiments 1 to 54.
[0266] Aspect 57: The method of aspect 50, wherein the cancer is pancreatic cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, nasopharyngeal cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, gastric adenocarcinoma, head cancer, neck cancer, brain cancer, oral cancer, pharyngeal cancer, thyroid cancer, esophageal cancer, gallbladder cancer, liver cancer, rectal cancer, kidney cancer, uterine cancer, bladder cancer, testicular cancer, lymphoma, myeloma, melanoma, leukemia, or a non-specific solid tumor.
[0267] Embodiment 58: A method for reducing a tumor in a subject, comprising administering to the subject a stereocomplex according to any one of embodiments 1 to 54.
[0268] Embodiment 59: A method according to any one of embodiments 56 to 58, wherein the stereocomplex is administered to the subject by intravenous injection.
[0269] Aspect 60: Component I has the following structure: [ka] (In the formula, n 1 is 45 to 90, m 1 is 15 to 60, o is 1 to 4; C a The stereochemistry in is R or S. having Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; q is 1 to 7; C a The stereochemistry in is R or S. having The ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9. 60. The method according to any one of embodiments 56 to 59.
[0270] Embodiment 61: The method of embodiment 60, wherein o is 2, each p is 2, and q is 3. EXAMPLES
[0271] The following examples are presented to provide those skilled in the art with a complete disclosure and description of how the compounds, compositions and methods described and claimed herein are made and evaluated, and are intended to be purely illustrative and are not intended to limit the scope of what the inventor regards as his invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but some error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, temperatures are in ° C. or are at ambient temperature, and pressures are at or near atmospheric pressure. Numerous variations and combinations of reaction conditions (e.g., concentrations of components, desired solvents, solvent mixtures, temperatures, pressures, and other reaction ranges and conditions) can be used to optimize product purity and yields obtained from the described processes. Only reasonable and routine experimentation will be required to optimize such process conditions. Example 1 Synthesis of polymer-conjugated drugs Synthesis of mPEG-PD / LLA:
[0272] mPEG-PD / LLA copolymers were synthesized by ring-opening polymerization using mPEG-OH as an initiator. Briefly, in a flame-dried and nitrogen-purged flask, distilled mPEG (M n =2000) and recrystallized D / L-lactide were added. Stannous octoate (in toluene) and toluene were added sequentially to the flask, after which the sealed flask was maintained at 120°C for 24 hours. The synthesized polymer was recovered by precipitation in ice-cold diethyl ether. The resulting precipitate was filtered and dried under vacuum at room temperature, and the yield was calculated to be 90%. Synthesis of DM1-SS-COOH:
[0273] Mertansine (DM1) and 3-(pyridin-2-yldisulfanyl)propanoic acid were dissolved in N,N-dimethylacetamide (the stoichiometric molar ratio of DM1 to 3-(pyridin-2-yldisulfanyl)propanoic acid was 1:2), followed by the addition of acetic acid (10 μL / mL of reaction solution). After stirring at 35° C. for 24 h under nitrogen atmosphere, the reaction solution was cooled to room temperature and then dialyzed against deionized water. After lyophilization, the resulting product was obtained and used in the next step without further purification, with a calculated yield of 88%. A schematic diagram of the synthesis is shown in FIG. 4. Synthesis of mPEG-PDLA-SS-DM1:
[0274] mPEG-PDLA copolymer, DM1-SS-COOH, DCC and DMAP were dissolved in dry dichloromethane and cooled in an ice bath (stoichiometric molar ratio of mPEG-PDLA:DM1-SS-COOH:DCC:DMAP is 1:1:2:2). The reaction was stirred under nitrogen at 0° C. for 48 h, then filtered and concentrated under reduced pressure. DM1-conjugated mPEG-PDLA was recovered by precipitation in cold diethyl ether and dried under vacuum. Gel permeation chromatography (GPC) with THF as the mobile phase was used to remove free DM1-SS-COOH, and the yield was calculated to be 64%. A schematic of the synthesis is shown in FIG. 4. FIG. 5 shows the structure of the purified product. 1 H NMR is shown. Synthesis of DTX-LEV:
[0275] Docetaxel (DTX) was esterified with LEV at the 2'-hydroxyl of DTX to give the respective ester derivative. Briefly, EDC·HCl and LEV were dissolved in dichloromethane under stirring at 4 °C for 30 min. Then, a dichloromethane solution of DTX and DMAP was added to the reaction (the stoichiometric molar ratio of DTX:EDC·HCl:DMAP:LEV was 1:2:2:2). The reaction was kept stirring overnight at 4 °C under nitrogen atmosphere. After washing twice with 0.05 N HCl and once with saturated NaCl, the organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give the product in 77% yield. A schematic diagram of the synthesis is shown in Figure 6. Synthesis of DTX-hydrazone-OH:
[0276] The hydrazone-containing derivative of DTX was realized by the reaction of DTX-LEV and 4-hydroxybutane hydrazide. Briefly, DTX-LEV and 4-hydroxybutane hydrazide were dissolved in anhydrous methanol under stirring at 45°C (the stoichiometric molar ratio of DTX-LEV:4-hydroxybutane hydrazide was 1:10). After the addition of acetic acid (10 μL / mL of reaction solution), the reaction was carried out for 2 h. The reaction solution was then cooled to room temperature and washed with saturated NaHCO3 to remove acetic acid and unreacted 4-hydroxybutane hydrazide, followed by extraction with acetyl acetate, dehydration with anhydrous NaSO4, and concentration under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography using CH2Cl2:MeOH (90:10) as the mobile phase in 72% yield. The schematic diagram of the synthesis is shown in Figure 6. Synthesis of mPEG-PLLA-COOH:
[0277] Succinic anhydride, DMAP, and mPEG-PLLA were dissolved in dichloromethane, and then TEA (the stoichiometric molar ratio of mPEG-PLLA:succinic anhydride:DMAP:TEA was 1:2:2:2) was added. After 24 hours at room temperature, the reaction solution was diluted with 0.1 M The mixture was washed twice with HCl and deionized water to remove DMAP and unreacted succinic anhydride, then dried over anhydrous Na2SO4 and concentrated under reduced pressure. The resulting mPEG-PLLA-COOH was recovered by precipitation in cold diethyl ether in 78% yield. A schematic diagram of the synthesis is shown in Figure 6. Synthesis of mPEG-PLLA-hydrazone-DTX:
[0278] Distilled mPEG-PLLA-COOH, DTX-hydrazone-OH, DCC and DMAP were dissolved in dry dichloromethane and cooled in an ice bath (stoichiometric molar ratio of mPEG-PLLA-COOH:DTX-hydrazone-OH:DCC:DMAP is 1:1.2:2:2). The reaction was stirred at 0° C. under nitrogen atmosphere for 48 h, then filtered and concentrated under reduced pressure. DTX-conjugated mPEG-PLLA was recovered by precipitation in cold diethyl ether and dried under vacuum. The final product was purified by preparative gel permeation chromatography using THF as the mobile phase. The yield was calculated to be 60%. A schematic of the synthesis is shown in FIG. 6. FIG. 7 shows the elution profile of the purified product. 1 H NMR is shown. Synthesis of mPEG-PLLA-ester-DTX:
[0279] Distilled mPEG-PLLA-COOH (previously described), DTX, DCC and DMAP were dissolved in dry dichloromethane and cooled in an ice bath (stoichiometric molar ratio of mPEG-PLLA-COOH:DTX:DCC:DMAP was 1:2:2:2). The reaction was stirred at 0° C. under nitrogen for 48 h, then filtered and concentrated under reduced pressure. DTX-conjugated mPEG-PLLA was recovered by precipitation in cold diethyl ether and dried under vacuum. GPC with THF as the mobile phase was used to remove free DTX. The yield was calculated to be 42%. Figure 8 shows the fraction of the purified product. 1 H NMR is shown. Synthesis of DTX-SS-pyridine:
[0280] DTX was esterified to the 2'-hydroxyl of DTX with 3-(pyridin-2-yldisulfanyl)propanoic acid to give the respective ester derivatives. Briefly, DTX, 3-(pyridin-2-yldisulfanyl)propanoic acid, CMPI and DMAP were dissolved in anhydrous CHCl (the stoichiometric molar ratio of DTX:3-(pyridin-2-yldisulfanyl)propanoic acid:CMPI:DMAP was 1:1:1.2:2.4). The reaction mixture was stirred at 40° C. for 1 h. The resulting reaction solution was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography using CHCl:acetyl acetate (50:50) as the mobile phase in 80% yield. A schematic diagram of the synthesis is shown in FIG. 9. Synthesis of DTX-SS-COOH:
[0281] DTX-SS-pyridine and 3-mercaptopropanoic acid were dissolved in N,N-dimethylacetamide (the stoichiometric molar ratio of DTX-SS-pyridine, 3-mercaptopropanoic acid is 1:1.1), followed by the addition of acetic acid (10 μL / mL of reaction solution). The reaction solution was stirred at 35° C. for 24 h under nitrogen atmosphere, then cooled to room temperature and dialyzed against deionized water. After lyophilization, the resulting product was obtained and used in the next step without further purification. The yield was estimated to be about 75%. A schematic diagram of the synthesis is shown in FIG. 9. Synthesis of mPEG-PLLA-SS-DTX:
[0282] The distilled mPEG-PLLA copolymer, DTX-SS-COOH, DCC and DMAP were dissolved in dry dichloromethane and cooled in an ice bath (stoichiometric molar ratio of mPEG-PLLA:DTX-SS-COOH:DCC:DMAP is 1:1.2:2.4:2.4). The reaction was stirred under nitrogen atmosphere from 0° C. to room temperature for 48 h, then filtered and concentrated under reduced pressure. The resulting mPEG-PLLA-SS-DTX conjugate was recovered by precipitation in cold diethyl ether and dried under vacuum. GPC with THF as the mobile phase was used to remove free DTX-SS-COOH. A schematic of the synthesis is shown in FIG. 9. Synthesis of HOOC-PEG-PDLA:
[0283] HOOC-PEG-PDLA copolymers were synthesized by ring-opening polymerization using COOH-PEG-OH as the initiator. Briefly, in a flame-dried and nitrogen-purged flask, distilled HOOC-PEG (M n =3500) and recrystallized D-lactide were added. Stannous octoate (in toluene) and toluene were added sequentially to the flask, after which the sealed flask was maintained at 120°C for 24 hours. The synthesized polymer was recovered by precipitation in ice-cold diethyl ether. The resulting precipitate was filtered and dried under vacuum at room temperature with a yield of 88%. Synthesis of cRGD-amide-PEG-PDLA:
[0284] HOOC-PEG-PDLA was dissolved in DMF and activated with HBTU under stirring at room temperature for 1 h, followed by the addition of a DMF solution of cRGD and DIEA (the stoichiometric molar ratio of HOOC-PEG-PLLA:cRGD:HBTU:DIEA was 1:1.1:3:3). After 24 h at room temperature under nitrogen atmosphere, the reaction was filtered and recovered by precipitation in ice-cold diethyl ether. The resulting precipitate was redissolved in DMF and dialyzed against water. After lyophilization, the resulting cRGD-amide-PEG-PDLA was obtained in 75% yield. Figure 10 shows the structure of the purified product. 1 H NMR is shown. Synthesis of Maleimide-PEG-PDLA:
[0285] Maleimide-PEG-PDLA copolymers were synthesized by ring-opening polymerization using maleimide-PEG-OH as the initiator. Briefly, in a flame-dried and nitrogen-purged flask, distilled maleimide-PEG (M n =3500) and recrystallized D-lactide were added. Stannous octoate (in toluene) and toluene were added sequentially to the flask, after which the sealed flask was maintained at 120°C for 24 hours. The synthesized polymer was recovered by precipitation in ice-cold diethyl ether. The resulting precipitate was filtered and dried under vacuum at room temperature. The yield was calculated to be 67%. Synthesis of cRGD-S-PEG-PDLA:
[0286] Maleimide-PEG-PDLA and cRGDfc were dissolved in DMF (the stoichiometric molar ratio of maleimide-PEG-PDLA:cRGDfc was 1:1.2). The reaction mixture was stirred overnight at room temperature under nitrogen atmosphere. The final mixture was dialyzed against deionized water. After lyophilization, the resulting cRGD-maleimide-PEG-PDLA was obtained. Synthesis of Folate-NH2:
[0287] Folate was dissolved in DMSO, followed by the addition of NHS and DCC. After activation at 50° C. in the dark under nitrogen for 6 hours, a DMSO solution of ethane-1,2-diamine and pyridine was added to the reaction mixture (stoichiometric molar ratio of folate:ethane-1,2-diamine:NHS:DCC:pyridine is 1:2:2:2:1). The reaction was then allowed to proceed for 24 hours at room temperature. The mixture was filtered, precipitated in ACN, and left at 4° C. overnight, followed by centrifugation (4000 rpm, 5 min). The solid was washed twice with ethanol, dried under vacuum, and then used in the next step without further purification. The yield was estimated to be 58%. Synthesis of folate-amide-PEG-PL / DLA:
[0288] Distilled HOOC-PEG-PL / DLA (previously described), NHS and EDC·HCl were dissolved in DMSO. The reaction mixture was stirred overnight at room temperature under nitrogen atmosphere. Then, a DMSO solution of folate-NH2 was added to the mixture, which was then kept in the dark at room temperature for 24 hours (stoichiometric molar ratio of HOOC-PEG-PL / DLA:folate-NH2:NHS:EDC·HCl:pyridine was 1:2:1.5:1.5). The final mixture was dialyzed against DMSO and water sequentially. After lyophilization, the resulting folate-amide-PEG-PL / DLA was obtained in 53% yield. Figure 11 shows the structure of the purified product. 1 H NMR is shown. Synthesis of Glu-PEG-PDLA:
[0289] HOOC-PEG-PDLA, methyl α-D-glucopyranoside and lipase 435 were suspended in acetonitrile. The mixture was homogenized at 50°C for 5 days. The enzyme was filtered off, followed by evaporation of the solvent. The residue was dissolved in CHCl and washed with deionized water. The organic phase was dried over anhydrous NaSO and concentrated. The resulting Glu-PEG-PDLA conjugate was recovered by precipitation in cold diethyl ether in 80% yield. Figure 12 shows the structure of the purified product. 1 H NMR is shown. Example 2 Preparation of stereocomplexes Preparation of D-DM1 formulations
[0290] mPEG-PDLA-SS-DM1 was dissolved in 0.5 mL DMF and 0.5 mL DMSO at a concentration of 20 mg / mL. The solution was added dropwise to Di-PBS. After stirring for 1 h at room temperature, the mixture was transferred to a dialysis membrane (cut-off 3.5K) and the solvent was removed by dialysis against PBS for 2 days. After filtration using a 450 nm filter, the size of the D-DM1 formulation was characterized by dynamic light scattering (Zetasizer from Malvern Instruments, Malvern, UK). The concentration of DM1 was tested by HPLC utilizing DTT. Briefly, 100 μl of D-DM1 solution was lyophilized to a powder. The powder was then dissolved using 1 mL of DMF solution containing 40 mM DTT and sonicated for 30 min. The content of DM1 was evaluated using a RP-HPLC system with UV detection at 254 nm using a mixture of acetonitrile and water (v / v, 60 / 40) as the mobile phase. The standard curve for DM1 was calculated as Y = 14.51448X-15.43867 (Y = peak area; X = DM1 concentration; r 2 = 0.99709; 1-50ug / ml). Preparation of L-DTX formulations
[0291] mPEG-PLLA-hydrazone-DTX was dissolved in 1 mL DMSO at a final concentration of 30 mg / mL. The DMSO solution was added dropwise to Di-PBS. After stirring for 1 h at room temperature, the mixture was transferred to a dialysis membrane (cut-off 3.5 K) and the solvent was removed by dialysis against PBS for 2 days. After filtration using a 450 nm filter, the size of the L-DTX formulation was characterized by dynamic light scattering (Zetasizer from Malvern Instruments, Malvern, UK). The concentration of DTX was tested by HPLC after alkaline degradation. Briefly, L-DTX sample solution (80 μL), 6 M NaOH (200 μL) and water (220 μL) were added sequentially to a 15 ml centrifuge tube. The mixture was incubated in a water bath at 60 °C overnight. Then, 6 M formic acid (250 μL) was added and the volume of the solution was adjusted to 3 mL with water. A solution containing benzoic acid, derived from the decomposition of DTX in alkaline solution, was used for HPLC. The mobile phase was ammonium acetate (20 mM) and methanol in a ratio of 90:10. The column effluent was detected at 230 nm. A calibration curve was prepared using standards of benzoic acid dissolved in methanol. The conversion ratio in mass of DTX:benzoic acid is 6.62:1. The calibration curve for benzoic acid is Y=5.8601X-3.9858 (Y=peak area, X=DTX concentration; r2=0.99871; 6.62-132.4 μg / mL). Preparation of complex formulations
[0292] mPEG-PLLA-hydrazone-DTX was dissolved in 2 mL THF at a concentration of 17 mmol. mPEG-PDLA-SS-DM1 was dissolved in 2 mL DMF at a concentration of 2.3 mmol for mPEG-PDLA-SS-DM1 and 13.5 mmol for mPEG-PDLA, respectively, with or without mPEG-PDLA. After mixing the THF and DMF solutions, the mixture was stirred at room temperature for 4 hours and then added dropwise to Di-PBS. After stirring at room temperature for 1 hour in a fume hood to evaporate as much THF as possible, the mixture was transferred to a dialysis membrane (cutoff 3.5K) and the solvent was removed by dialysis against PBS for 2 days. After filtration using a 450 nm filter, the size of the complex was characterized by dynamic light scattering (Zetasizer, from Malvern Instruments, Malvern, UK). The method used for concentrating DM1 and DTX in the complex was the same as that used in the prodrug formulation. The lyophilized powder was successfully reconstituted from the complex solution without the use of any lyoprotectant, and the concentrations of DTX and DM1 in the complex formulation are 6.63 mmol and 0.95 mmol, respectively.
[0293] In the second step, mPEG-PLLA-hydrazone-DTX was dissolved in 2 mL of THF at a concentration of 17 mmol. mPEG-PDLA-SS-DM1 was dissolved in 2 mL of acetonitrile with or without mPEG-PDLA at concentrations of 2.3 mmol for mPEG-PDLA-DM1 and 10.5 mmol for mPEG-PDLA, respectively. After mixing the THF and acetonitrile solutions, the mixture was stirred at room temperature for 4 h and then added dropwise to Di-PBS. After stirring at room temperature for 1 h, the organic solvent was rotary evaporated under vacuum. After lyophilization and reconstitution, the concentrations of DTX and DM1 in the complex are 7.79 mmol and 1.08 mmol, respectively. Preparation of glucose formulations containing the complex
[0294] mPEG-PLLA-hydrazone-DTX was dissolved in 2 mL THF at a concentration of 17 mmol. mPEG-PDLA-SS-DM1 and Glu-PEG-PDLA were dissolved in 2 mL DMF at a concentration of 2.3 mmol for mPEG-PDLA-DM1 and 25 mmol for Glu-PEG-PDLA, respectively. After mixing the THF and DMF solutions, the mixture was stirred at room temperature for 4 hours and then added dropwise to Di-PBS. After stirring at room temperature for 1 hour and rotary evaporation at room temperature under vacuum to remove as much solvent as possible, the mixture was transferred to a dialysis membrane (cutoff 3.5 K) and dialyzed against PBS for 2 days to remove residual organic solvents. After filtration using a 450 nm filter, the size of the complexes was characterized by dynamic light scattering (Zetasizer from Malvern Instruments, Malvern, UK). The lyophilized powder was successfully reconstituted from the glucose-containing complex solution without the use of any cryoprotectant, and the concentrations of DTX and DM1 in the complex formulation are 5.37 mmol and 0.745 mmol, respectively. Example 3 In vitro release test
[0295] The release of poly-DTX was carried out by dialysis in phosphate buffered saline (pH 7.4 and 5.5, containing 0.2% w / v polysorbate 80). Briefly, 1 mL of poly-DTX formulation with a concentration of docetaxel adjusted to 3 mg / mL with PBS was placed in a dialysis bag (MWCO=3.5 kDa) which was sealed. After immediate immersion in 10 mL of release medium, the sample was incubated at 37°C. At fixed time intervals (4, 8, 24, 48 h), 1 mL of external release medium was taken and replenished with an equal amount of fresh medium.
[0296] The cumulative release of DTX was indirectly measured by quantifying the content of benzoic acid (one of the stable final degradation products of DTX) by HPLC. Briefly, the solution withdrawn from the release medium was lyophilized, dissolved in 6 M NaOH (0.25 mL), and incubated overnight at 60° C. in a water bath. Finally, 6 M formic acid (0.25 mL) was added, and the mixture was filtered through a 0.45 μm PTFE filter for HPLC detection. The mobile phase consisted of ammonium acetate (20 mM) and methanol in a ratio of 90:10. The column effluent was detected at 230 nm. A calibration curve was prepared using standards of benzoic acid dissolved in methanol. The conversion ratio by mass of DTX:benzoic acid is 6.62:1. The calibration curve for benzoic acid was calculated for concentrations ranging from 6.62 to 132.4 μg / mL with the equation Y = 4.92334X-3.53882 (Y = peak area, X = DTX concentration; r 2 =0.99976).
[0297] The release of poly-DM1 was performed by dialysis in phosphate buffered saline (pH 7.4, containing 0.2% w / v polysorbate 80) with or without 10 mM glutathione (GSH). Briefly, 1 mL of poly-DM1 formulation, with a concentration of DM1 adjusted to 0.5 mg / mL with PBS, was placed in a dialysis bag (MWCO=3.5 kDa) which was sealed. After immediate immersion in 10 mL of release medium, the samples were incubated at 37°C. At fixed time intervals (4, 8, 24, 48 h), 1 mL of external release medium was taken and replenished with an equal amount of fresh medium. All released samples were lyophilized and the amount of released DM1 was determined using HPLC measurements as previously described. Example 4 DM1 and DTX combination index
[0298] Combination index was calculated for free DM1 and DTX in various cell lines at various ratios of DM1 to DTX. As used herein, "combination index" or "CI" refers to the quantitative determination of combination drugs. The results are classified as synergistic (condition CI<1), additive effect (condition CI=1), and antagonism (condition CI>1). The tests were performed in human alveolar basal adenocarcinoma cells, (A549), non-small cell lung cancer cells (NCI-H460), pancreatic cancer cells (MiA PaCa-2), gastric cancer cells (SGC-7901), and liver cancer cells (Hep3B2.1-7). The combination index results for these five cell lines are shown in Figure 13, with various drug ratios on the horizontal axis and combination index on the vertical axis. Example 5 Dynamic Light Scattering to Determine Particle Size
[0299] The particle size of the stereocomplex and the individual component molecules was determined using dynamic light scattering. Figure 14A shows the particle size of the prodrugs mPEG-PDLA-SS-DM1 and mPEG-PLLA-hydrazone-DTX. Figure 14B shows the particle size of the complex formed by dialysis (left panel) and after lyophilization and reconstitution (right panel). The size of the complex is about 80 nm. Figure 14C shows the particle size of the complex formed by using rotary evaporation (left panel) and after lyophilization and reconstitution (right panel). The size of the complex is about 50 nm. Example 6 Differential scanning calorimetry to determine melting temperatures
[0300] Differential scanning calorimetry (DSC) was used to determine the melting temperatures of the prodrug, precursor molecule, and stereocomplex. The DSC results are shown in Figures 15A-15B. Figure 15A shows the DSC profiles of free DM1 powder (blue line), lyophilized powder of mPEG-PDLA (black line), and the prodrug of mPEG-PDLA-DM1 (red line). DM1 has a melting temperature of 177°C, while PDLA has a melting temperature of about 120°C. Figure 15B shows the melting temperature profiles for the prodrug mPEG-PLLA-DTX (black line), mPEG-PDLA-DM1 (red line), and the stereocomplex formed between the two (blue line). A new melting temperature of 186°C is seen in the DSC profile of the stereocomplex, indicating a strong interaction between PDLA and PLLA during stereocomplex formation. Example 7 Release of DTX and DM1 over time
[0301] The release of DTX over time from the stereocomplex was measured at pH 7.4 (squares) and pH 5.5 (circles). The results are presented in Figure 16A. Conjugation of DTX with a pH-sensitive hydrazone linker results in faster release of DTX at pH 5.5 than at the near-neutral pH of 7.4.
[0302] The release of DM1 over time from stereocomplexes with and without glutathione (GSH) was measured at pH 7.4. The results are presented in FIG. 16B. DM1 is released most rapidly from the isolated prodrug in the presence of GSH (squares) and more slowly from the stereocomplex (circles). In the absence of glutathione, DM1 is essentially not released from either the isolated prodrug or the complex (triangles and inverted triangles at 0% cumulative release). Thus, conjugation of DM1 with a redox-sensitive disulfide linker prevents premature release of DM1 without GSH. Example 8 Tolerance of the formulation in tumor-free mice
[0303] Healthy mice (n=5 for each treatment group) were injected into the tail vein with either 4 mg / kg DM1-containing prodrug, 4 mg / kg DM1-containing prodrug and mPEG-PLLA, or a stereocomplex containing 4 mg / kg DM1 and 27 mg / kg DTX per injection on days 1, 8, 15, and 22 of the 28-day study, and body weight was monitored to determine tolerability of the treatment. Body weight increased slightly on average with the DM1-containing prodrug, but two mice showed tail swelling and ulceration on days 8–14 (squares). One mouse in the prodrug and PLLA treatment group died on day 4, and treatment in this group was discontinued (circles). Body weight decreased slightly on average with stereocomplex treatment, but remained within 5% change. No tail swelling or ulceration was observed in the stereocomplex treatment group (triangles). The results are shown in Figure 17A. Healthy mice (n=5 for each treatment group) were injected with the complexes once per week at 3.6 mg / kg DM1 for a total of three injections, once per two weeks at 5 mg / kg DM1 for a total of two injections, and once only at 7 mg / kg DM1, respectively. As shown in Figure 17B, no obvious weight loss was observed in any treatment group over the course of 21 days. Example 9 Tumor size in treated and control groups
[0304] A human gastric cancer cell suspension (BGC-823) was injected subcutaneously into the back of the mouse to establish a tumor model. 3Upon reaching the age of 18 days, groups of tumor-bearing mice (n=5) were injected with stereocomplexes via the tail vein on the days indicated by the arrows in panel (a) (i.e., 1, 8 and 15 at doses of 4 mg / kg DM1 and 36 mg / kg DTX per injection). Figure 18A shows tumor size measurements for the control group (squares) and the treated group (circles). No significant weight loss was observed in either the treated or control groups (Figure 18B). Significant tumor reduction was achieved in the complex group (resected tumors are illustrated in Figure 18C), with a greater overall reduction in tumor weight achieved in the stereocomplex-treated group (Figure 18D). Example 10 Antitumor efficacy and toxicity in pancreatic tumor models
[0305] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous MiA PaCa-2 pancreatic tumor model. The MiA PaCa-2 cell suspension was injected subcutaneously into the back of the mice to establish the tumor model. The tumor volume was approximately 140 mm 3 Upon reaching 10 days, groups of tumor-bearing mice (n=5) were injected via the tail vein on days 1 and 14 of the approximately 40-day study. After 24 days, one treated mouse was tumor-free, and a total of three mice were tumor-free after 38 days. After tumor regression, no recurrence was observed during the study period. The change in tumor size is presented in Figure 19A, and Figure 19B shows photos of mice in the control group (top row) and treated group (bottom row) on day 29. Example 11 Comparison of antitumor efficacy in pancreatic tumor models
[0306] The antitumor efficacy and toxicity of the stereocomplexes and DM1-containing prodrugs were evaluated in a subcutaneous MiaPaCa-2 pancreatic tumor model. MiAPaCa-2 cell suspensions were injected subcutaneously into the back of mice to establish the tumor model. Tumor volumes of approximately 140 mm 3Upon reaching 10 days, groups of tumor-bearing mice (n=5) were injected with the treatment via the tail vein. Almost identical antitumor effects were observed after four injections in the case of the DM1-containing prodrug (D-DM1) and two injections in the case of the stereocomplex. However, D-DM1 treatment induced mouse death and obvious weight loss, and this treatment group was terminated after the fourth injection for humane reasons. On the contrary, the stereocomplex treatment group showed an increase in body weight during the entire period, indicating the general safety of the treatment. The results are presented in Figures 20A-20B. Figure 20A shows the tumor volumes for the control group (squares), the D-DM1 prodrug group (circles) and the stereocomplex treatment group (triangles). Figure 20B shows the body weights for the control group (squares), the D-DM1 prodrug group (circles) and the stereocomplex treatment group (triangles). Example 12 Antitumor efficacy and toxicity in liver tumor models
[0307] The antitumor efficacy and toxicity of the stereocomplexes were evaluated in a subcutaneous Hep 3B2.1-7 liver tumor model. Hep 3B2.1-7 cell suspensions were injected subcutaneously into the back of mice to establish the tumor model. Tumor volumes of approximately 130 mm 3 Upon reaching the target tumor mass, groups of tumor-bearing mice (n=5) were injected with the treatment via the tail vein. In this model, the body weight of the control group decreased with increasing tumor size. The body weight of the stereocomplex-treated group remained normal throughout the study period. After treatment, one mouse from the stereocomplex-treated group was tumor-free, and the average tumor weight of the stereocomplex-treated group (n=5) was only 4.5% of the average tumor weight of the control group (n=3) (two mice died before the end of the study due to the formation of very large tumors).
[0308] The results are presented in Figures 21A-21D. Figure 21A shows the tumor volumes of the control group (squares) and the stereocomplex-treated group (circles), and the arrows indicate the injection dates of the treatment groups at a dose of 4 mg / kg DM1 and 28 mg / kg DTX per injection. Figure 21B shows the body weights of the control group (squares) and the stereocomplex-treated group (circles). Figure 21C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 21D shows a comparison of the tumor weights of the control group (left) and the stereocomplex-treated group (right). Example 13 Antitumor efficacy and toxicity in colon tumor models
[0309] The antitumor efficacy and toxicity of the stereocomplexes were evaluated in a subcutaneous HT-29 colon tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and tumors were allowed to grow to approximately 100 mm 3 Once tumors were detected, groups of mice (n=5) bearing tumors were injected with the composition via the tail vein. Figure 22A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed smaller final tumor volumes (arrows indicate injection days at doses of 4 mg / kg DM1 and 32 mg / kg DTX per injection). Figure 22B shows the weight changes of the control and treated groups. Figure 22C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 22D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). Example 14 Comparison of antitumor efficacy in nasopharyngeal tumor models
[0310] The antitumor efficacy and toxicity of the stereocomplexes and DM1-containing prodrugs were evaluated in a subcutaneous CNE nasopharyngeal tumor model when the treatment was delivered by intravenous injection. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model. When the tumor volume was approximately 100 mm 3Upon reaching 100 mg / kg, groups of tumor-bearing mice (n=5) were injected with the complex via the tail vein. Figure 23 shows that tumor volume was significantly increased in the D-DM1 prodrug treated group after four injections of 4 mg / kg DM1 once per week, while mice treated with the complex showed smaller final tumor volume after four injections of 4 mg / kg DM1 and 26 mg / kg DTX once per week. Example 15 Antitumor efficacy and toxicity in small cell lung tumor models
[0311] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous NCI-H526 small cell lung tumor model. The tumor model was established by subcutaneous injection of NCI-H526 cell suspension into the back of mice. The tumor volume was approximately 100 mm 3 Upon reaching the age of 18 days, a group of tumor-bearing mice (n=5) was injected once a week via the tail vein. After three injections of 3.8 mg / kg DM1 and 32 mg / kg DTX once a week, one mouse was tumor-free on day 18 and all mice were tumor-free from day 32. Figure 24A shows the tumor size change for the group treated with the complex (red line) versus the control group (black line). Figure 24B shows the control mice (top row of photos) and treated mice (bottom row of photos) on day 18 of the study. (Example 16) Antitumor efficacy and toxicity in non-small cell lung tumor models
[0312] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous NCI-H1975 non-small cell lung tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and the tumors grew to approximately 130 mm 3Once tumor-bearing mice were inoculated with the composition via the tail vein, groups of mice (n=5) were injected with the composition. Figure 25A shows that untreated mice (black line) showed a more significant increase in tumor volume, while mice treated with the complex (red line) showed a smaller final tumor volume after only one injection of 5 mg / kg DM1 and 33 mg / kg DTX. Figure 25B shows the weight changes of the control and treatment groups. Figure 25C shows the resected tumors of the control group (top row) and the stereocomplex-treated group (bottom row), and it is noted that in the treatment group, one mouse was tumor-free at the end of the study. Figure 25D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). (Example 17) Antitumor efficacy and toxicity in a triple-negative breast tumor model
[0313] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous MDA-MB-231 triple-negative breast tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and the tumors were approximately 100 mm 3 Once tumor-bearing mice were inoculated with the composition via the tail vein, groups of mice (n=6) were injected with the composition. Figure 26A shows that untreated mice (squares) showed a more significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume after only one injection of 2.5 mg / kg DM1 and 18 mg / kg DTX. Figure 26B shows the weight changes of the control and treated groups. Figure 26C shows the resected tumors of the control group (top row) and the stereocomplex-treated group (bottom row), and it is noted that one mouse was tumor-free from day 23 until the end of the study. Figure 26D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). (Example 18) Antitumor efficacy and toxicity in breast tumor models
[0314] The in vivo antitumor efficacy of the complex in large tumors was evaluated in a subcutaneous MX-1 breast tumor model. The tumor model was established by subcutaneous injection of cell suspension into the back of mice. The tumor volume was approximately 530 mm 3 Upon reaching the age of 10 days, a group of tumor-bearing mice (n=5) was injected with the complex via the tail vein. After only one injection of 6 mg / kg DM1 and 42 mg / kg DTX, the tumor size decreased continuously over the next 20 days, as shown in Figure 27A, demonstrating the efficacy of the complex even in large tumors. No weight loss was observed with this treatment (Figure 27B). (Example 19) Antitumor efficacy and toxicity in breast tumor models
[0315] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous MCF-7 breast tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and the tumors were approximately 100 mm 3 Once the tumors were detected, groups of mice (n=8) with tumors were injected with the composition via the tail vein. Figure 28A shows the tumor volume change of the untreated group (black line) and the group treated with the complex (red line) after two injections (arrows indicate the injection days of each injection at 5 mg / kg DM1 and 30 mg / kg DTX). Figure 28B shows no difference in body weight change between the control and treated groups. Figure 28C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row), noting that one mouse was tumor-free from day 25 and three mice were tumor-free at the end of the study. Figure 28D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). (Example 20) Antitumor efficacy and toxicity in bladder tumor models
[0316] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous RT112 bladder tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and the tumors were approximately 100 mm 3Once tumors were detected, groups of mice (n=5) bearing tumors were injected with the composition via the tail vein. Figure 29A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume after three injections of 3.6 mg / kg DM1 and 30 mg / kg DTX once per week. Figure 29B shows the weight changes of the control and treated groups. Figure 29C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 29D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). Example 21 Antitumor efficacy and toxicity in esophageal tumor models
[0317] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous TT esophageal tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and the tumors grew to approximately 110 mm 3 Once tumors were detected, groups of mice (n=5) bearing tumors were injected with the composition via the tail vein. Figure 30A shows that untreated mice (squares) experienced a significant increase in tumor volume, while mice treated with the complex experienced rapid tumor shrinkage after three injections of 4 mg / kg DM1 and 40 mg / kg DTX once per week. Figure 30B shows the weight changes of the control and treated groups. Figure 30C shows the resected tumors of the control group (top row) and the stereocomplex-treated group (bottom row), and it is noted that one mouse was tumor-free from day 27 onwards. Figure 30D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). Example 22 Antitumor efficacy and toxicity in glioblastoma tumor models
[0318] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous U251 globlastoma tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and the tumors were approximately 150 mm 3Once tumors had developed, groups of mice (n=5) bearing tumors were injected with the composition via the tail vein. Figure 31A shows that untreated mice (squares) showed a significant increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume after two injections of 3 mg / kg DM1 and 30 mg / kg DTX once per week. Figure 31B shows the weight changes of the control and treated groups. Figure 31C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 31D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). (Example 23) Antitumor efficacy and toxicity in renal tumor models
[0319] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous Caki-1 kidney tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and the tumors grew to approximately 170 mm 3 Once tumors had formed, groups of mice (n=5) bearing tumors were injected with the composition via the tail vein. Figure 32A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume after three injections of 3.2 mg / kg DM1 and 32 mg / kg DTX once per week. Figure 32B shows the weight changes of the control and treated groups. Figure 32C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 32D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). (Example 24) Antitumor efficacy and toxicity in non-small cell lung tumor models
[0320] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous NCI-H522 non-small cell lung tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and the tumors were approximately 130 mm 3Once the tumors had reached the tumor-bearing mice, groups (n=5) were injected with the composition via the tail vein. Figure 33A shows that the tumor volume increased significantly in untreated mice (squares), whereas the tumor volume dropped sharply in mice treated with the complex after two injections of 5 mg / kg DM1 and 50 mg / kg DTX once per week. Figure 33B shows the weight changes in the control and treated groups. Figure 33C shows the resected tumors in the control group (top row) and the stereocomplex-treated group (bottom row), and it should be noted that three mice were tumor-free at the end of the study. Figure 33D shows a comparison of the tumor weights in the control group (left) and the stereocomplex-treated group (right). (Example 25) Antitumor efficacy and toxicity in non-small cell lung tumor models
[0321] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous NCI-H226 non-small cell lung tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and the tumors were approximately 120 mm 3 Once tumors were detected, groups of mice (n=4) bearing tumors were injected with the composition via the tail vein. Figure 34A shows that untreated mice (squares) showed a greater increase in tumor volume, while mice treated with the complex (circles) showed a smaller final tumor volume after two injections of 4 mg / kg DM1 and 32 mg / kg DTX once every two weeks. Figure 34B shows the weight changes of the control and treated groups. Figure 34C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 34D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). (Example 26) Antitumor efficacy and toxicity in ovarian tumor models
[0322] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous ovcar-3 ovarian tumor model. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, and the tumors were approximately 150 mm 3Once tumors had formed, groups of mice (n=5) bearing tumors were injected with the composition via the tail vein. Figure 35A shows that untreated mice (squares) showed a significant increase in tumor volume, while mice treated with the complex (circles) showed a small final tumor volume after only one injection of 6 mg / kg DM1 and 39 mg / kg DTX. Figure 35B shows the weight changes of the control and treated groups. Figure 35C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 35D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). Example 27 Antitumor efficacy and toxicity in prostate tumor models
[0323] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous PC-3 prostate tumor model. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model, and the tumors grew to approximately 130 mm 3 Once tumor-bearing mice were inoculated with the composition via the tail vein, groups of mice (n=5) were injected with the composition. Figure 36A shows that untreated mice (squares) showed a significant increase in tumor volume, while mice treated with the complex (circles) showed a small final tumor volume after three injections of 3.8 mg / kg DM1 and 38 mg / kg DTX once per week. Figure 36B shows that mice in the control group lost weight, while the treated group maintained normal weight. Figure 36C shows the excised tumors of the control group (top row) and the stereocomplex-treated group (bottom row). Figure 36D shows a comparison of tumor weights of the control group (left) and the stereocomplex-treated group (right). (Example 28) Antitumor efficacy and toxicity in lymphoma tumor models
[0324] The in vivo antitumor efficacy of the complex was evaluated in a subcutaneous Raji lymphoma tumor model by intravenous injection. The cell suspension was injected subcutaneously into the back of the mice to establish the tumor model. The tumor volume was approximately 130 mm 3Upon reaching the age of 18 days, groups of tumor-bearing mice (n=4) were injected with the complex via the tail vein. After only one injection with 5 mg / kg DM1 and 40 mg / kg DTX, three mice were tumor-free on day 15 and all mice were tumor-free from day 22 onwards. Figure 37A shows the tumor size change for the complex-treated group (circles) versus the control group (squares). Figure 37B shows photographs of the control mice (top row) and treated mice (bottom row) on day 25 of the study. (Example 29) Blood parameters and clinical chemistry tests after a single injection of the complex
[0325] Mice (4 per group) were injected with the complex at a single iv dose of 5 mg / kg DM1 and 32.5 mg / kg DTX, then sacrificed on days 3, 7 and 14. Blood samples were collected and analyzed for the following general parameters: white blood cell count (WBC); red blood cell count (RBC); hemoglobin concentration (HGB) and platelet count (PLT). Compared with the control (no injection) labeled day 0, RBC and HGB showed no statistical difference in all studies. Even if lower WBC and PLT counts were observed on day 3, they all recovered on day 7 and remained normal on day 14, as shown in Figure 38.
[0326] Figure 39 shows clinical chemistry in nude mice after a single iv injection of the complex. Mice (4 per group) were injected with the complex at a single iv dose of 5 mg / kg DM1 and 32.5 mg / kg DTX, then sacrificed on days 3, 7 and 14. Blood samples were collected and analyzed for the following parameters: alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP), creatinine (CREA) and urea (UREA). Compared to the control (no injection) labeled day 0, ALT and AST were elevated after injection, but returned to normal on day 14. There was no obvious difference in UREA and CREA, which means there was no nephrotoxicity. (Example 30) Histopathological analysis of organs after multiple injections of the complex
[0327] A CNE (nasopharyngeal) tumor cell suspension was injected subcutaneously into the back of the mice to establish the tumor model, so that the tumors grew to approximately 100 mm 3 Then, groups of tumor-bearing mice (n=5) were injected weekly via tail vein with the composition for 4 consecutive weeks at a dose of 4mg / kg DM1 for D-DM1 group and 4mg / kg DM1 with 26mg / kg DTX for complex group. After harvesting the heart, kidney, spleen, lung and liver, the sections were stained with hematoxylin and eosin for observation. As shown in Figures 40 and 41, compared with the control and D-DM1 treatment, the complex treatment did not induce any damage to the organs. (Example 31) Antitumor efficacy and toxicity of glucose-containing complexes in lymphoma tumor models
[0328] The in vivo antitumor efficacy of the glucose-containing complex was evaluated in a subcutaneous Raji lymphoma tumor model by intravenous injection. The cell suspension was injected subcutaneously into the back of the mouse to establish the tumor model. The tumor volume was approximately 130 mm 3 Upon reaching the age of 18 days, groups of tumor-bearing mice (n=4) were injected with the complex via the tail vein. After only one injection with 5 mg / kg DM1 and 40 mg / kg DTX, three mice were tumor-free on day 15 and all mice were tumor-free from day 18. Figure 42A shows the tumor size change for the group treated with the complex (red line) versus the control group (black line). Figure 42B shows photographs of the control mice (top row) and the mice treated with the glucose-containing complex (bottom row) on day 25 of the study. Example 32 patient research Preparation and administration of stereocomplexes
[0329] mPEG-PLLA-hydrazone-DTX was dissolved in 2 mL of THF, and mPEG-PDLA-SS-DM1 was dissolved in 2 mL of acetonitrile together with mPEG-PDLA. The two solutions were mixed together, and the mixture was stirred at room temperature for 4 hours, and then added dropwise to Di-PBS. After stirring at room temperature for 1 hour, the organic solvent was rotary evaporated under vacuum. After evaporation, the stereocomplex was lyophilized, and the powder was reconstituted with water and filtered through a 200 nm filter for sterilization. The weight percentage of DM1 was about 0.8% and the weight percentage of DTX was about 6%, which means that the weight ratio of DTX to DM1 was 7-9.
[0330] Aqueous solutions of the stereocomplexes were mixed with saline (500 mL) for intravenous injection. The stereocomplexes were administered intravenously to each patient for approximately 1 hour. The stereocomplexes were administered approximately every 2 weeks after the first treatment. The amounts of DM1 and DTX administered to each patient varied as follows: total amount of DM1 was measured and expressed in mg / m 2 is the body surface area calculated for height and weight. As noted below, patient 1 received 4 mg / m 2 Therefore, the patient received 1.2m 2 For a subject with a body surface area (BSA) of 100 mg, the total DM1 administered is 4.8 mg. As presented above, the weight percentage of DM1 in the stereocomplex is about 0.8% by weight of the stereocomplex, which means that the total weight of the stereocomplex administered to the subject is about 600 mg (4.8 / 0.8). patient 1
[0331] The first patient was a 71-year-old man with squamous cell lung cancer. From the AJCC cancer staging classification of PET-CT study, the lung cancer was classified as stage 3 with a hypermetabolic subbronchial nodule in the right lower lobe. Four treatments (4 mg DM1 / m per treatment) based on the PET-CT study were administered. 2) the intensity of the subcarinal lymph nodes was significantly reduced as shown in Figure 43. The patient underwent right total lobectomy. The 38 adjacent lymph nodes that were removed were normal with no evidence of tumor in the pathology report and the cancer was classified pathologically as stage 1. No further procedures were performed after surgery and the individual was normal after 4 months of follow-up based on PET-CT scan. patient 2
[0332] The second patient was a 70-year-old man with pancreatic cancer. At the start of the study, the size of the pancreatic head mass was 3.68 cm × 3.77 cm × 4.26 cm as confirmed by MR imaging (axial and coronal planes) and biopsy revealed adenocarcinoma of the pancreas. Stereocomplex (4 mg DM1 / m 2 After treatment with Stereocomplex (4 mg DM1 / m per treatment), the size of the pancreatic mass was 3.19 cm × 3.27 cm as confirmed by contrast-enhanced CT (axial plane), which is a 25% reduction in cross-sectional area. 2 After five procedures with MRI, the individual underwent a Whipple procedure. The surgical specimen revealed a 2 cm × 1.5 cm pancreatic head tumor, representing an approximate 80% reduction in cross-sectional area compared with the initial MR imaging. patient 3
[0333] The third patient is a 6-year-old boy with diffuse pontine glioma (DIPG). Initially, the boy was treated with hyperfractionated radiotherapy with a total dose of 54 Gray (Gy) in 30 daily fractions. Leptomeningeal metastases were subsequently noted by MR, and grade 4 diffuse pontine glioma was confirmed by stereotactic biopsy. Prior to treatment with stereocomplex, sagittal MR of the spine showed multiple large irregularly shaped masses occupying most of the spinal canal from L1 to S1, with minimally visible CSF spaces. Stereocomplex (10 mg DM1 / m per treatment) was administered. 2After five treatments with CT, MR revealed significant tumor mass reduction in the spinal canal between L1 and S1, representing approximately a 93% reduction in tumor volume in this region. Only a small residual mass was noted behind L4 and L5, with the CSF space and cauda equina nerve fibers easily identifiable (Figure 44). patient 4
[0334] The fourth patient is a 70-year-old man with non-small cell lung cancer. At the beginning of the study, the tumor size was 3.3 cm x 2.9 cm as confirmed by PET / CT. Immediately after the first treatment, the tumor size increased to 3.5 cm x 2.8 cm as confirmed by PET / CT. Stereocomplex (12 mg DM1 / m per treatment) 2 After two treatments with , the PET / CT scans examined confirmed that the long diameter of the tumor had decreased from 3.5 cm to 2.2 cm in 15 days, as shown in Figure 45. The uptake of mediastinal, hilar and abdominal aortic lymph nodes changed to normal (Figure 46). Notably, before treatment, the tumor was found to have invaded the parietal pleura, but after treatment, the tumor size was reduced and the tumor and parietal pleura were found to be completely separated (Figure 47).
[0335] Throughout this publication, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the methods, compositions, and compounds herein.
[0336] Various modifications and variations can be made to the materials, methods, and articles described herein. Other aspects of the materials, methods, and articles described herein will be apparent from consideration of the specification and practice of the materials, methods, and articles disclosed herein. It is intended that the specification and examples be considered as illustrative. The present invention provides, for example, the following items. (Item 1) Components X 1 -Y 1 -L 1-Z 1 (I) X 2 -Y 2 -L 2 -Z 2 (II) (In the formula, each X 1 and X 2 is a hydrophilic group, Each Y 1 and Y 2 is PDLA or PLLA, Each L 1 and L 2 is a cleavable linker, Z 1 is an anticancer drug, Z 2 is an anti-cancer agent or an imaging agent, where Z 2 If is an anticancer drug, Z 1 and Z 2 are different anticancer drugs, and Here, (1) Y 1 If is PDLA, then Y 2 is PLLA, and Y 1 If is PLLA, Y 2 is PDLA, and (2) the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9. Stereo complex including. (Item 2) X 1 and X 2 are different hydrophilic groups. (Item 3) X 1 and X 2 are the same hydrophilic group. (Item 4) X 1 and X 2 and each is a polyalkylene glycol. (Item 5) X1 and X 2 and each of the above is a polyalkylene glycol having a molecular weight of 1,000 Da to 5,000 Da. (Item 6) X 1 and X 2 and each of them is a polyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da. (Item 7) X 1 and X 2 and each of them is monomethoxypolyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da. (Item 8) 8. The stereocomplex according to any one of items 1 to 7, wherein PDLA and PLLA have a molecular weight of 700 Da to 5,000 Da. (Item 9) L 1 and L 2 9. The stereocomplex according to any one of the preceding claims, wherein are different linkers. (Item 10) L 1 and L 2 are the same linker. (Item 11) L 1 and L 2 9. The stereocomplex according to any one of the preceding claims, wherein independently contains a disulfide group, an ester group, a hydrazone group, an acetal group, an imine group, a β-thiopropionate group or an amide group. (Item 12) Z 1 and Z 2is independently paclitaxel, doxorubicin, gemcitabine, cisplatin, methotrexate, 5-fluorouracil, betulinic acid, amphotericin B, diazepam, nystatin, propofol, testosterone, estrogen, prednisolone, prednisone, 2,3 mercaptopropanol, progesterone, docetaxel, maytansinoid, PD-1 inhibitor, PD-L1 inhibitor, protein kinase inhibitor, P-glycoprotein inhibitor, autophagy inhibitor, PARP inhibitor, aromatase inhibitor, monoclonal antibody, photosensitizer, radiosensitizer, interleukin, antiandrogen, or any combination thereof. (Item 13) 13. The stereocomplex according to item 12, wherein the maytansinoid is ansamitocin, mertansine (DM1) or ravtansine. (Item 14) Z 1 and Z 2 14. The stereocomplex according to any one of items 1 to 13, wherein the molar ratio of (Item 15) Z 1 is mertansine, and Z 2 15. The stereocomplex according to any one of items 1 to 14, wherein is docetaxel. (Item 16) For component I, X 1 is a monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, the number of L-lactic acid units or D-lactic acid units is 15 to 60, and L 1 contains a disulfide group, and Z 1 16. The stereocomplex according to any one of the preceding items, wherein is mertansine (DM1). (Item 17) Component I has the following structure: [ka] (In the formula, n 1is 45 to 90, m 1 is 15 to 60, o is 1 to 4, and C a The stereochemistry in is R or S. Item 17. The stereocomplex according to item 16, having the formula: (Item 18) 18. The stereocomplex according to item 17, wherein o is 2. (Item 19) Regarding component II, X 2 is a monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, the number of L-lactic acid units or D-lactic acid units is 15 to 60, and L 2 contains an ester, hydrazone, or disulfide group, and Z 2 19. The stereocomplex according to any one of items 16 to 18, wherein is docetaxel. (Item 20) 20. The stereocomplex according to item 19, wherein the molar ratio of mertansine to docetaxel is 4:1 to 1:10. (Item 21) Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, p is 0 to 7, and C a The stereochemistry in is R or S. 20. The stereocomplex according to item 19, having the formula: (Item 22) 22. The stereocomplex according to item 21, wherein p is 2. (Item 23) Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; q is 1 to 7; C a The stereochemistry in is R or S. 20. The stereocomplex according to item 19, having the formula: (Item 24) 24. The stereocomplex according to item 23, wherein each p is 2 and q is 3. (Item 25) Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; C a The stereochemistry in is R or S. 20. The stereocomplex according to item 19, having the formula: (Item 26) 26. The stereocomplex according to item 25, wherein each p is 2. (Item 27) The stereocomplex is represented by component VII X 3 -Y 3 (VII) (In the formula, X 3 is a hydrophilic group, and Y 3 is PDLA or PLLA) 27. The stereocomplex according to any one of the preceding claims, further comprising: (Item 28) X 3is a polyalkylene glycol having a molecular weight of 1,000 Da to 5,000 Da. (Item 29) X 3 is a polyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da. (Item 30) X 3 is a monomethoxypolyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da. (Item 31) X 3 is a monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, and the number of L-lactic acid units or D-lactic acid units present in PDLA or PLLA is 15 to 60. (Item 32) The stereocomplex is represented by component VIII TA-X 4 -Y 4 (VIII) (In the formula, X 4 is a hydrophilic group, Y 4 is PDLA or PLLA, and TA is a targeting group 32. The stereocomplex according to any one of the preceding claims, further comprising: (Item 33) X 4 is a polyalkylene glycol having a molecular weight of 1,000 Da to 5,000 Da, where X 4 The molecular weight of X 1 and X 2 33. The stereocomplex according to item 32, having a molecular weight of greater than or equal to (Item 34) X 4 is a polyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da, where X 4 The molecular weight of X1 and X 2 33. The stereocomplex according to item 32, having a molecular weight of greater than or equal to (Item 35) X 4 is a polyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, and the number of L-lactic acid units or D-lactic acid units present in PDLA or PLLA is 15 to 60. (Item 36) 33. The stereocomplex according to item 32, wherein TA is a ligand. (Item 37) The component VIII has the structure: [ka] (In the formula, n 3 is 45 to 90, m 3 is between 15 and 60, and C a The stereochemistry in is R or S. 33. The stereocomplex according to item 32, having the formula: (Item 38) 33. The stereocomplex according to item 32, wherein TA is an unsubstituted or substituted sugar. (Item 39) 39. The stereocomplex according to item 38, wherein the sugar is ribose, galactose, mannose, fructose, fuculose, glucosamine or fucoidan. (Item 40) 33. The stereocomplex according to item 32, wherein TA is glucose or a substituted glucose. (Item 41) 41. The stereocomplex according to item 40, wherein TA is an alkyl-substituted glucose. (Item 42) 41. The stereocomplex according to item 40, wherein TA is methyl-α-glucose or methyl-β-glucose. (Item 43) The stereocomplex has the formula IX X 5 -Y 5 -L 5 -Z 5 (IX) (In the formula, X 5 is a hydrophilic group, Y 5 is PDLA or PLLA, L 5 is a cleavable linker, and Z 5 is an anticancer drug, where Z 5 is Z 1 and Z 2 is different from 43. The stereocomplex according to any one of the preceding claims, further comprising one or more components: (Item 44) Z 2 is an imaging agent and said imaging agent comprises a radiopharmaceutical, a radiological contrast agent, an optical imaging agent or a precursor thereof, a quantum dot or a combination thereof. (Item 45) The radiopharmaceutical is 11 CL-methyl-methionine, 18 F-fluorodeoxyglucose, 18 F - sodium fluoride, 18 F fluorocholine, 18 F Desmethoxyfalipride, 67 Ga-Ga 3+ , 68 Ga-dotatoc, 68 Ga-PSMA, 111 In-Diethylenetriaminepentaacetic acid, 111 In-white blood cells, 111 In-platelets, 111 In-Penetreotide, 111 In-Octreotide, 123 I-iodide, 123 Io-iodohiplate, 123 Im-iodobenzylguanidine,123 I-FP-CIT, 125 I-fibrinogen, 131 I-iodide, 131 Im-iodobenzylguanidine, 81 Kr m -gas, 81 Kr m -aqueous solution, 13 N-ammonia, 15 O-water, 75 Se-selenolcholesterol, 75 Se-seleno-25-homo-tauro-cholate, 120 Tl-Tl + , 133 Xe-gas, 133 Xe (in isotonic sodium chloride solution), 99 Tc m -Pertechnetate, containing macroaggregates or microspheres 99 Tc m - human albumin, 99 Tc m phosphonates and / or phosphates, 99 Tc m -diethylenetriaminepentaacetic acid, 99 Tc m -dimercaptosuccinic acid, 99 Tc m -colloid, 99 Tc m -Hepatic iminodiacetic acid, 99 Tc m whole red blood cells, 99 Tc m -Mercaptoacetyltriglycine, containing Examethazime-labeled leukocytes 99 Tc m Examethadim, 99 Tc m Sesta-methoxyisobutylisonitrile, 99 Tc m IMMU-MN3 mouse Fab'-SH anti-granulocyte monoclonal antibody fragment; 99 Tc m -Technegas, 99 Tc m Human immunoglobulin, 99 Tc m - tetrofosmin, 99Tc m - A stereocomplex according to item 44, comprising ethyl cysteinate dimer, or another radiopharmaceutical. (Item 46) 45. The stereocomplex according to item 44, wherein the radiocontrast agent comprises diatrizoate, metrizoate, iothalamate, ioxaglate, iopamidol, iohexol, ioxilan, iopromide, iodixanol, ioversol, another iodine contrast agent, barium sulfate, gadoterate, gadodiamide, gadobenate, gadopentetate, gadoteridol, gadofosveset, gadoversetamide, gadoxetate, gadobutrol or another gadolinium chelator. (Item 47) Item 48. The stereocomplex according to item 44, wherein the optical imaging agent or precursor thereof comprises methylene blue, indigo carmine, another non-specific dye, fluorescein isothiocyanate, indocyanine green, rosamine, BODIPY (boron-dipyrromethane) derivative, chalcone, xanthone, oxazole yellow, thiazole orange, fluorescein, luciferin, Texas red, squaraine, porphyrin, phthalocyanine, polymethine cyanine dyes including Cy3, Cy5, Cy5.5 or Cy7, Alexa fluor, 5-aminolevulinic acid, a metal chelator or another optical imaging agent. 48. The stereocomplex according to any one of the preceding claims, further comprising an adjuvant. (Item 49) 49. The stereocomplex according to item 48, wherein the adjuvant comprises an interstitial disrupting agent, an antifibrotic agent, an aromatase inhibitor, an immunosuppressant, an estrogen blocker, a gonadotropin releasing hormone agonist, an estrogen modulator, a progestin therapeutic agent, an LHRH agonist, an androgen reducing agent, an antiandrogen, an immunosuppressant or any combination thereof. (Item 50) Item 49. The stereocomplex according to item 48, wherein the adjuvant comprises a stromal-rupturing agent, wherein the stromal-rupturing agent comprises losartan, azilsartan, candesartan, eprosartan, irbesartan, olmesartan, telmisartan, valsartan, luteolin, quercetin, genistein, catechin, cyaniding, naringenin, delphinidin, malvidin, petunidin, peonidin, pelargonidin, gallocatechin, catechin-3-gallate, epicatechin, epigallocatechin, daidzein, glycitein, equol, kaempferol, myricetin, eriodictyol, hesperitin, taxifolin, or any combination thereof. (Item 51) Item 49. The stereocomplex according to item 48, wherein the adjuvant comprises an antifibrotic agent, wherein the antifibrotic agent comprises pirfenidone, mimosine, ciclopirox, diodon, bemeglide, deferiprone, etanercept, bosentan, sildenafil, nintedanib, colchicine or a combination thereof. (Item 52) Component I has the following structure: [ka] (In the formula, n 1 is 45 to 90, m 1 is 15 to 60, o is 1 to 4, and C a is R or S), and Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; q is 1 to 7, and C aThe stereochemistry in is R or S. having wherein the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9; Item 1. A stereocomplex according to item 1. (Item 53) 53. The stereocomplex according to item 52, wherein o is 2, each p is 2, and q is 3. (Item 54) 54. The stereocomplex according to any one of items 1 to 53, wherein the stereocomplex has an average diameter of 50 nm to 200 nm. (Item 55) 55. A pharmaceutical composition comprising a stereocomplex according to any one of items 1 to 54 and a pharma- ceutically acceptable carrier. (Item 56) 55. A method for treating cancer in a subject, comprising administering to the subject a stereocomplex according to any one of items 1 to 54. (Item 57) 57. The method of claim 56, wherein the cancer is pancreatic cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, nasopharyngeal cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, gastric adenocarcinoma, head cancer, neck cancer, brain cancer, oral cancer, pharyngeal cancer, thyroid cancer, esophageal cancer, gallbladder cancer, liver cancer, rectal cancer, kidney cancer, uterine cancer, bladder cancer, testicular cancer, lymphoma, myeloma, melanoma, leukemia, or nonspecific solid tumor. (Item 58) 55. A method for reducing a tumor in a subject, comprising administering to the subject a stereocomplex according to any one of items 1 to 54. (Item 59) 59. The method of any one of items 56 to 58, wherein the stereocomplex is administered to the subject by intravenous injection. (Item 60) Component I has the following structure: [ka] (In the formula, n 1 is 45 to 90, m 1 is 15 to 60, o is 1 to 4, and C a The stereochemistry in is R or S. and Component II has the following structure: [ka] (In the formula, n 2 is 45 to 90, m 2 is 15 to 60, each p is independently 0 to 7; q is 1 to 7; C a The stereochemistry in is R or S. having wherein the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.9; 60. The method according to any one of items 56 to 59. (Item 61) Item 61. The method according to item 60, wherein o is 2, each p is 2, and q is 3.
Claims
1. A stereo complex, Components X 1 -Y 1 -L 1 -Z 1 (I) X 2 -Y 2 -L 2 -Z 2 (II) (In the formula, Each X 1 and X 2 is a polyalkylene glycol, Each Y 1 and Y 2 is PDLA or PLLA, Each L 1 and L 2 is a cleavable linker independently selected from a disulfide group, an ester group, a hydrazone group, an acetal group, an imine group, a β-thiopropionate group, or an amide group; Z 1 is an anticancer drug, Z 2 is an imaging agent, and Here, (1) Y 1 If is PDLA, then Y 2 is PLLA, and Y 1 When Y is PLLA, 2 is PDLA, and (2) the ratio of the total number of D-lactic acid units in the stereocomplex to the total number of L-lactic acid units in the stereocomplex is 0.9:1.1 to 1.1:0.
9. Stereo Complex, including.
2. X 1 and X 2 are different polyalkylene glycols or are the same polyalkylene glycol, preferably X 1 and X 2 are each polyalkylene glycol having a molecular weight of 1,000 Da to 5,000 Da, more preferably each polyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da, or each monomethoxypolyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da. A stereocomplex as claimed in claim 1,
3. 3. The stereocomplex as claimed in claim 1 or 2, wherein each of PDLA and PLLA has a molecular weight of 700 Da to 5,000 Da.
4. L 1 and L 2 A stereocomplex as claimed in any one of the preceding claims, wherein are different linkers or are the same linker.
5. Z 1 is paclitaxel, doxorubicin, gemcitabine, cisplatin, methotrexate, 5-fluorouracil, betulinic acid, amphotericin B, diazepam, nystatin, propofol, testosterone, estrogen, prednisolone, prednisone, 2,3-mercaptopropanol, progesterone, docetaxel, maytansinoid, PD-1 inhibitor, PD-L1 inhibitor, protein kinase inhibitor, P-glycoprotein inhibitor, autophagy inhibitor, PARP inhibitor, aromatase inhibitor, monoclonal antibody, photosensitizer, radiosensitizer, interleukin, antiandrogen, or any combination thereof, the PD-1 inhibitor is pembrolizumab, nivolumab, pidilizumab, AMP-224, AMP-514 or PDR001; the PD-L1 inhibitor is atezolizumab, avelumab, durvalumab or BMS0936559; the protein kinase inhibitor is afatanib, axitinib, bosutinib, cetuximab, cobimetinib, crizotinib, cabozantinib, dasatinib, entrectinib, erlotinib, fostamatinib, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, mubritinib, nilotinib, pazopanib, pegaptanib, ruxolitinib, sorafenib, sunitinib, SU6656, vandetanib or vemurafenib; The p-glycoprotein inhibitors include verapamil, cyclosporine, tamoxifen, calmodulin antagonists, dexverapamil, dexniguldipine, valspodar (PSC833), biliquidar (VX-710), tariquidar (XR9576), zosuquidar (LY335979), laniquidar (R101933), elacridar (GF120918), timcodar (VX-853), taxifolin, naringenin, dios amine, quercetin, diltiazem, bepridil, nicardipine, nifedipine, felodipine, isradipine, trifluoperazine, clopenthixol, trifluopromazine, flupentixol, emopamil, gallopamil, Ro11-2933, amiodarone, clarithromycin, colchicine, erythromycin, lansoprazole, omeprazole, paroxetine, sertraline, quinidine, or any combination thereof; the autophagy inhibitor is 3-methyladenine, wortmannin, LY294002, PT210, GSK-2126548, spautin-1, SAR405, VPS34-IN1, PIK-III, MRT68921, SBI-0206965, pepstatin A, E64d, bafilomycin A1, clomipramine, lucanthone, chloroquine, hydroxychloroquine, Lys05, or ARN5187; the PARP inhibitor is MK-4827, rucaparib, iniparib, talazoparib, olaparib, veliparib, CEP9722, E7016, BGB2-290 or 3-aminobenzamide; the aromatase inhibitor is aminoglutethimide, testolactone, anastrozole, letrozole, exemestane, vorozole, formestane, fadrozole, 1,4,6-androstatriene-3,17-dione or 4-androstene-3,6,17-trione; Preferably, the maytansinoid is ansamitocin, mertansine (DM1) or ravtansine, more preferably Z 1 is mertansine. A stereocomplex as claimed in any one of the preceding claims.
6. Z 1 and Z 2 A stereocomplex as claimed in any one of the preceding claims, wherein the molar ratio of is from 10:1 to 1:
10.
7. Regarding component I, X 1 is a monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, the number of L-lactic acid units or D-lactic acid units is 15 to 60, and L 1 contains a disulfide group, and Z 1 is mertansine (DM1), and preferably component I has the following structure: 【Chemistry 23】 (wherein n 1 is 45 to 90; m 1 is 15 to 60; o is 1 to 4, preferably 2, and The stereochemistry at C a is R or S. having A stereocomplex as claimed in any one of the preceding claims.
8. Regarding component II, X 2 is a monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, the number of L-lactic acid units or D-lactic acid units is 15 to 60, and L 2 The stereocomplex as claimed in claim 7, wherein comprises an ester, hydrazone, or disulfide group.
9. The stereocomplex is represented by component VII ︸ 3 3 (().) (In the formula, X 3 is a polyalkylene glycol, preferably a polyalkylene glycol having a molecular weight of 1,000 Da to 5,000 Da, more preferably a polyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da or a monomethoxypolyethylene glycol having a molecular weight of 1,000 Da to 5,000 Da; and Y 3 is PDLA or PLLA) and most preferably, X 3 is monomethoxypolyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, and the number of L-lactic acid units or D-lactic acid units present in the PDLA or PLLA is 15 to 60. A stereocomplex as claimed in any one of the preceding claims.
10. The stereocomplex is represented by the formula: () 4 4 (().|) (In the formula, X 4 is a polyalkylene glycol, preferably having a molecular weight of 1,000 Da to 5,000 Da, where the molecular weight of X 4 is greater than that of X 1 and X 2 , or more preferably a polyethylene glycol, having a molecular weight of 1,000 Da to 5,000 Da, where the molecular weight of X 4 is greater than that of X 1 and X 2 ; Y 4 is PDLA or PLLA, and TA is a targeting group, said targeting group being an antibody, an antibody fragment, an aptamer, a sugar, a peptide, a lectin, folic acid, a folate, or a steroid hormone. and most preferably, X 4 is a polyethylene glycol having a molecular weight of 2,000 Da to 4,000 Da, and the number of L-lactic acid units or D-lactic acid units present in the PDLA or PLLA is 15 to 60. A stereocomplex as claimed in any one of the preceding claims.
11. The component VIII has the structure: 【Chemistry 27】 (In the formula, n 3 is 45 to 90, m 3 is between 15 and 60, and C a The stereochemistry at is R or S.
11. The stereocomplex as claimed in claim 10, having the following structure:
12. 11. The stereocomplex as claimed in claim 10, wherein TA is an unsubstituted or substituted sugar, preferably said sugar is ribose, galactose, mannose, fructose, fuculose, glucosamine or fucoidan, or TA is glucose or a substituted glucose, preferably an alkyl-substituted glucose, more preferably methyl-α-glucose or methyl-β-glucose.
13. the imaging agent comprises a radiopharmaceutical, a radiological contrast agent, an optical imaging agent or a precursor thereof, a quantum dot, or any combination thereof; Preferably, said radiopharmaceutical is selected from the group consisting of 11 C-L-methyl-methionine, 18 F-fluorodeoxyglucose, 18 F-sodium fluoride, 18 F fluorocholine, 18 F desmethoxyphalipride, 67 Ga-Ga 3+ , 68 Ga-dotatoc, 68 Ga-PSMA, 111 In-diethylenetriaminepentaacetic acid, 111 In-leukocytes, 111 In-platelets, 111 In-penetreotide, 111 In-octreotide, 123 I-iodide, 123 I-o-iodohiprate, 123 I-m-iodobenzylguanidine, 123 I-FP-CIT, 125 I-fibrinogen, 131 I-iodide, 131 I-m-iodobenzylguanidine, 81 Kr m -gas, 81 Kr m -aqueous solution, 13 N-ammonia, 15 O-water, 75 Se-selenolcholesterol, 75 Se-seleno-25-homo-tauro-cholate, 120 Tl-Tl + , 133 Xe-gas, 133 Xe (in isotonic sodium chloride solution), 99 Tc m -pertechnetate, 99 Tc m -human albumin including macroaggregates or microspheres, 99 Tc m phosphonates and / or phosphates, 99 Tc m -diethylenetriaminepentaacetic acid, 99 Tc m -dimercaptosuccinic acid, 99 Tc m -colloids, 99 Tc m -liver iminodiacetic acid, 99 Tc m whole red blood cells, 99 Tc m -mercaptoacetyltriglycine, 99 Tc m exercisetazidyme including exercisetazidyme-labelled white blood cells, 99 Tc m sester-methoxyisobutylisonitrile, 99 Tc m IMMU-MN3 mouse Fab'-SH anti-granulocyte monoclonal antibody fragment, 99 Tc m -technegas, 99 Tc m human immunoglobulin, 99 Tc m -tetrofosmin, or 99 Tc m -ethyl cysteine dimer, or The radiological contrast agent preferably comprises diatrizoate, metrizoate, iothalamate, ioxaglate, iopamidol, iohexol, ioxilan, iopromide, iodixanol, ioversol, an iodine contrast agent, barium sulfate, gadoterate, gadodiamide, gadobenate, gadopentetate, gadoteridol, gadofosveset, gadoversetamide, gadoxetate, gadobutrol or a gadolinium chelator, or The optical imaging agent or precursor thereof preferably comprises methylene blue, indigo carmine, a non-specific dye, fluorescein isothiocyanate, indocyanine green, rosamine, BODIPY (boron-dipyrromethane) derivatives, chalcones, xanthones, oxazole yellow, thiazole orange, fluorescein, luciferin, Texas red, squaraines, porphyrins, phthalocyanines, polymethine cyanine dyes including Cy3, Cy5, Cy5.5 or Cy7, Alexa fluor, 5-aminolevulinic acid, or metal chelators. A stereocomplex as claimed in any one of the preceding claims.
14. The stereocomplex further comprises an adjuvant, wherein the adjuvant comprises a stromal disrupting agent, an anti-fibrotic agent, an aromatase inhibitor, an immunosuppressant, an estrogen blocker, a gonadotropin releasing hormone agonist, an estrogen modulator, a progestin therapeutic agent, an LHRH agonist, an androgen reducing agent, an antiandrogen, an immunosuppressant, or any combination thereof, preferably the adjuvant comprises a stromal disrupting agent, wherein the interstitial bursting agent is losartan, azilsartan, candesartan, eprosartan, irbesartan, olmesartan, telmisartan, valsartan, luteolin, quercetin, genistein, catechin, cyaniding, naringenin, delphinidin, malvidin, petunidin, peonidin, pelargonidin, gallocatechin, catechin-3-gallate, epicatechin, epigallocatechin, daidzein, glycitein, equol, kaempferol, myricetin, eriodictyol, hesperitin, taxifolin, or any combination thereof; the antifibrotic agent is pirfenidone, mimosine, ciclopirox, geodon, bemeglide, deferiprone, N-acetylcysteine, etanercept, bosentan, sildenafil, nintedanib, colchicine, or any combination thereof; the aromatase inhibitor is anastrozole, letrozole or exemestane; the immunosuppressant is a corticosteroid (hydrocortisone), methotrexate or interferon, and The estrogen blocker is tamoxifen, toremifene, or fulvestrant. A stereocomplex as claimed in any one of the preceding claims.
15. 2. A stereocomplex as claimed in any one of the preceding claims, wherein said stereocomplex has an average diameter of 50 nm to 200 nm as measured by dynamic light scattering.
16. A pharmaceutical composition comprising a stereocomplex as claimed in any one of the preceding claims and a pharma- ceutically acceptable carrier thereof.
17. 16. A composition comprising a stereocomplex as claimed in any one of claims 1 to 15 for use in the treatment of cancer in a subject, preferably wherein the cancer is pancreatic cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, nasopharyngeal cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, gastric adenocarcinoma, head cancer, neck cancer, brain cancer, oral cancer, pharyngeal cancer, thyroid cancer, esophageal cancer, gallbladder cancer, liver cancer, rectal cancer, kidney cancer, uterine cancer, bladder cancer, testicular cancer, lymphoma, myeloma, melanoma, leukemia or unspecified solid tumor.
18. A composition comprising a stereocomplex as claimed in any one of claims 1 to 15 for use in reducing a tumor in a subject.
19. 19. A composition for use as claimed in claim 17 or 18, wherein said composition is administered to said subject by intravenous injection.
